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Blood-soluble drag reducing polymers (DRPs) have been shown to produce considerable 
beneficial effects on blood circulation, including an increase in tissue perfusion and tissue 
oxygenation and a decrease in vascular resistance, when injected in blood at minute 
concentrations in animal models of normal and especially pathological circulation. DRPs have 
potential applications in treating tissue hypoperfusion caused by cardiovascular disease, stroke, 
peripheral vascular disease, diabetes, and other illnesses. To help to translate this novel therapy 
from the lab bench to the clinic, standard tests need to be developed for characterization and 
efficacy testing of candidate polymers. Furthermore, elucidation of the mechanisms of the 
observed DRP effects on blood circulation is extremely important for their future medical 
applications. Finally, effective, biocompatible and stable polymers which can be easily produced 
in large quantities must be identified. 
In this work a sequence of tests was developed to characterize and assess efficacy of 
DRPs for possible use in treating circulatory disorders. This research study also provided a better 
understanding of mechanical degradation of DRPs, especially in the presence of blood cells or 
particles. It was discovered that an increase in particle concentration led to an increase in 
degradation rate, and that rigid particles caused an even higher degradation rate than deformable 
red blood cells (RBCs). 
 
 iv 
Microfluidic studies in models of microvessels showed that DRPs prevented RBC 
movement from the walls of microchannels toward the center and lessened plasma skimming at 
bifurcations, delivering more RBCs to smaller branches and thus to capillaries. In vivo, this may 
lead to a reduction of the near-wall plasma layer, which would facilitate gas transport, increase 
local wall shear stress and promote vasodilation decreasing vascular resistance in microvessels.  
Three polymers, including an aloe vera derived polysaccharide (AVP), poly(N-vinyl 
formamide), and hyaluronic acid (HA), were evaluated and characterized as new drag reducers 
for potential clinical use and found to be very effective. HA and AVP were found to be the most 
resistant to mechanical degradation of the tested polymers. Finally, relaxation time and gyration 
radius were found to be the polymer’s physical properties which best predicted their drag 
reducing effectiveness.  
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1.0  INTRODUCTION 
Treatment of tissue hypoperfusion is extremely important for millions of patients suffering from 
cardiovascular disease, stroke, peripheral vascular disease, diabetes, and other illnesses. Standard 
therapies available today for treatment of tissue hypoperfusion include administration of 
vasopressive agents to enhance pressure and administration of inotropic agents to enhance 
myocardial contractility and cardiac output [1]. More advanced treatments of cardiovascular 
diseases are being developed using tissue engineering and regenerative medicine methods. In 
spite of significant progress in treatments of cardiovascular diseases and some decline in 
mortality due to these diseases, they are still major causes of death in the United States and other 
developed countries. The costs associated with treatment of these diseases and related disabilities 
are enormous. Thus, development of novel methods of enhancement of impaired 
microcirculation, which is the major cause of tissue hypoperfusion, is essential. The objective of 
this study was to develop special blood-soluble drag reducing polymers (DRPs) as a novel 
concept for improving inadequate microcirculation. Intravascular flow enhancement by DRP 
additives to blood has been demonstrated in vivo in experimental animals [1-14]. The remarkable 
ability of DRP additives to reduce/prevent the mortality of animals subjected to hemorrhagic 
shock and acute hypoxia and to significantly improve microcirculation in animal models of 
diabetes and myocardial infarction makes these polymers desirable candidates for new therapies 
for treatment of insufficient blood circulation of any origin.   
 1 
DRPs are soluble polymers which reduce resistance to turbulent flow in a pipe when 
added to flowing fluid at nanomolar concentrations [15]. Polymer drag reduction is a physical 
phenomenon that was discovered about 60 years ago and is still not completely understood. 
Blood-soluble DRPs have been shown to produce significant beneficial effects on animal blood 
circulation, including an increase in tissue perfusion and tissue oxygenation and a decrease in 
vascular resistance, when intravenously injected at minute concentrations (1 – 10 µg/ml). These 
polymers have been successfully applied in animal models of various pathologies including 
hemorrhagic shock, atherosclerosis, and diabetes [1-4, 6, 8, 9, 12, 14, 16, 17]. It was shown that 
the polymers did not affect blood viscosity and did not have a direct effect on the vessel tone. 
Several hypotheses regarding the mechanisms underlying the observed beneficial hemodynamic 
effects of DRPs were proposed in the past. It was first suggested that the DRPs may enhance 
fluidity of the blood by reducing resistance to turbulent flow in the vascular system, which may 
exist due to some pathological states. [18]. However, the DRP effect was seen in normal animals 
in which turbulent blood flow is not present. In vitro studies regarding DRP effects on flow 
separation in models of bifurcating vessels demonstrated that under flow conditions 
corresponding to realistic vascular hemodynamics (1≤ Reynolds number (Re) ≤ 800), DRPs 
reduced the size of the flow separation and delayed the development of vortices at bifurcations 
[19, 20]. In vivo, this phenomenon would reduce pressure loss in arterial vessels and thus 
increase precapillary pressure, thereby increasing the density of functional capillaries (tissue 
perfusion). However, the exact mechanisms underlying the DRP intravascular phenomenon 
remain incompletely understood. Several DRPs, including polyethylene oxides, polyacrylamides, 
and certain polysaccharides have been identified and applied in various in vivo models of 
circulation. These polymers are chemically dissimilar, but all possess drag reducing properties as 
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demonstrated in in vitro tests. Thus, the mechanisms underlying the demonstrated beneficial 
hemodynamic effects of DRPs are most likely based on the fluid dynamic and/or viscoelastic 
properties of the DRPs versus the actual chemistry of these polymers [1].   
Several DRPs have been shown to be effective in vivo including high molecular weight 
polyethylene oxide (PEO) [1, 3, 12, 14], polyacrylamide (PAM) [2, 4, 8, 9], and certain 
polysaccharides [1, 6, 17]. However, none of the tested DRPs were found, in their present form, 
to be ideal for biomedical applications. PEO was very effective in vivo, but rapidly mechanically 
degraded when exposed to turbulent flow and other high stress conditions. PAM was also shown 
to be effective in vivo and was relatively resistant to mechanical degradation. However, it was 
not a good DRP candidate for biomedical applications because of its reported toxicity [9, 12]. 
High molecular weight polysaccharides were also shown to be very effective in vivo [1, 6, 17] 
and resistant to mechanical degradation [21-23]. Additionally, polysaccharides as a class are 
generally non-toxic [24, 25]. However, currently there is no method for their production in large 
amounts. Therefore, it is essential to develop new DRPs for potential clinical use and to develop 
a set of tests to characterize these new DRPs and assess their properties required for the 
successful use in vivo.   
This project aimed to develop a biocompatible DRP suitable for biomedical applications, 
to make a significant step toward understanding the mechanisms of the intravascular DRP 
phenomenon, and to find physicochemical characteristics of DRPs necessary for in vivo 
efficiency. An ideal DRP preparation for biomedical applications, which is effective, 
biocompatible, mechanically stable, well defined, and reproducible during preparation, must be 
developed, and the mechanism responsible for the intravascular DRP effect must be identified in 
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order to translate this novel technology from the lab bench to the clinic. This development of 
DRPs for bioengineering applications was accomplished through the following specific aims: 
1) Develop a set of hydrodynamic, rheological, and molecular tests to characterize 
blood soluble drag reducing polymers 
To achieve this specific aim, a hydrodynamic system was developed for standardized 
testing of polymer drag reducing efficiency in saline or in blood, molecular properties of the 
DRPs were characterized using gel permeation chromatography (GPC), viscoelastic properties of 
DRPs were characterized using rheological methods, and the mechanical degradation of DRPs 
due to exposure to shear stress was characterized at a wide range of pipe flow conditions 
(Reynolds numbers). The developed series of tests was applied to a well-known DRP, PEO, and 
then to characterize and test new DRPs described in Specific Aim 3. 
2) Determine potential mechanisms of the intravascular effects of drag reducing 
polymers using in vitro microscale methods 
In order for DRPs to be applied in the medical field, it is important to have an 
understanding of the mechanism for their effects on hemodynamics. Therefore, an in vitro 
microscale method of testing the rheological efficacy of DRPs and of studying their mechanism 
was developed. Microchannel systems were fabricated, microfluidic studies of the DRP effects 
on flow of blood or suspensions of red blood cells (RBCs) were performed, and the data were fit 
to a model of RBC concentration distribution across the microchannel. 
3) Develop and test new drag reducing polymers  
Several DRPs, including high molecular weight PEOs, PAMs, and plant-derived 
polysaccharides were applied and found to be effective in blood circulation in previous in vivo 
studies. However, the search continues for new DRPs, which are biocompatible, mechanically 
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stable, well defined, and reproducible, for clinical use. Therefore, three novel blood soluble 
DRPs were characterized and tested for potential biomedical applications including a DRP 
derived from the aloe vera plant, poly(N-vinylformamide), and hyaluronic acid. Mechanical 
degradation behavior of the polymers was compared. Correlations were determined between 
physicochemical and rheological properties of these polymers and their drag reducing efficiency. 
The physical and molecular properties which best predict a polymer’s effectiveness in microflow 
systems and thus likely in vivo were also determined. 
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2.0  BACKGROUND 
2.1 DRAG REDUCING POLYMERS 
Various types of additives, including solid particles such as sands and fibers, colloidal systems 
like surfactants and soaps, and many soluble polymers both synthetic and natural, have been 
shown to reduce friction and, therefore, enhance fluid flow [26]. The class of soluble polymers, 
so called drag reducing polymers (DRPs), has been proven to be the most effective of the drag 
reducers. It was discovered several decades ago that the addition of minute concentrations of 
some special soluble polymers could significantly decrease resistance to flow without affecting 
viscosity or density of the fluid [15]. This phenomenon, known as the Toms effect, occurs in 
developed turbulent flow with DRPs that exhibit certain physicochemical properties. Figure 2-1 
shows the effect of DRPs, which cause a reduction in pressure gradient at a constant flow rate or 
an increase in flow at a constant pressure, on turbulent pipe flow when added to flowing water at 
the concentration of 10 µg/ml. Many organic and water-soluble long-chain polymers were found 
to have drag reducing properties. Small concentrations of these DRPs can reduce friction by up 
to 80% [26]. To possess drag reducing activity a polymer must have a high molecular weight 
(MW>106 Da) and at least a fairly linear structure [26]. At the same molecular weight, a linear 
polymer will be a more effective drag-reducer than a branched polymer [26]. Highly branched 
polymers, such as high molecular weight dextran, have no drag reducing ability. It is important 
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for the polymer to be in a good solvent that will extend the polymer coil and increase flexibility 
of the polymer chain. A poor solvent will cause a polymer to become rigid, inhibiting its drag 
reducing activity [26]. The polymer’s drag reducing efficiency is best defined by degree of 
polymerization, which describes the number of monomer units and therefore chain length. The 
number of backbone chain links is important in determining a DRP’s efficacy [27]. Therefore, if 
two polymers have the same molecular weight, the one with the lower molecular weight 
monomer will be the better drag-reducer [27].   
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Figure 2-1. Effect of DRPs on turbulent flow in a pipe.  
 
Kulicke [26] reviewed the properties required for an effective DRP in detail by analyzing 
primary, secondary, tertiary, and quaternary structure. He found, that average absolute molecular 
weight, which is represented by the weight average (Mw) or number average (Mn) molecular 
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weight and describes the primary structure, must be greater than 106 Da. In general, the high 
molecular weight tail of the distribution determines the polymer’s effectiveness as a drag-
reducer. Polymers that are more flexible, and therefore occupy a larger volume by forming a 
solvent filled coil, are more effective DRPs [26]. Polyelectrolytes, which have a larger 
hydrodynamic volume in distilled water than in salt solutions, exhibit better drag reducing 
efficiency with decreasing concentrations of salt [26]. Ionic groups, arranged with a certain 
structural orientation of charges, can also enhance a DRP’s activity [26]. It was found by Kinnier 
[28] that, to obtain the same drag reduction with polymers of different molecular weights, equal 
hydrodynamic volumes of the polymers are required.   
The DRPs do not have any effect on pipe laminar flow characteristics and do not change 
fluid viscosity at the effective concentrations. It was found, however, that DRP additives reduced 
hydrodynamic resistance in systems with nonturbulent (disturbed laminar) flow, such as 
pulsating flow in straight and spiral pipes or Couette flow with Taylor vortices at low Reynolds 
numbers [29, 30]. The class of DRPs includes organic polymers such as polymethylmethacrylate, 
polyisobutylene and polystyrene as well as several water soluble polymers. Well-known, 
effective, water soluble DRPs include synthetic polymers such as PEO, PAM, poly(acrylic acid), 
and natural polymers such as guar gum, xanthan, carboxymethylcellulose, DNA, hyaluronic acid, 
a polysaccharide from the okra plant [17], several algae [31], fish slimes [32, 33], and several 
bacterial polysaccharides [32]. More recently, a new DRP was discovered in the inner matter of 
the aloe vera leaves [34], which was later successfully applied in an animal model of a lethal 
hemorrhagic shock as an additive to a resuscitation fluid [1]. The Toms phenomenon has been 
investigated and used for various industrial and engineering applications including crude oil 
transport through pipelines, firefighting, and reducing drag on ships and submarines [35-37]. 
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After several decades of intensive studies, several theories have been proposed, but the exact 
mechanism of the Toms phenomenon is still unknown. 
2.2 INTRAVASCULAR EFFECTS OF DRPS 
While DRPs have been studied and applied in numerous industrial and engineering uses, their 
application in the biomedical area is not well known. It has been shown, however, that the same 
polymers that reduce resistance to turbulent flow also produce remarkable effects on blood 
circulation in vivo. Blood soluble DRPs, when injected in the vascular system at nanomolar 
concentrations, increase blood flow, tissue perfusion, and tissue oxygenation and reduce vascular 
resistance with no direct effect on blood viscosity or blood vessel tone [12, 16, 38]. Figure 2-2 
shows a typical record of the effect that a single intravenous injection of DRP, given to a normal 
animal, has on tissue perfusion and mean arterial blood pressure [39]. DRPs caused both an 
increase in tissue perfusion (top curve) and a slight decrease in the mean arterial pressure 
(bottom curve), which indicated that the microvascular resistance was decreased. In animal 
models of various pathological conditions, blood soluble DRPs have been applied and were 
found to produce beneficial effects on the vascular system including a significant increase (up to 
50%) in linear blood velocity in capillaries and in number of functioning capillaries in diabetic 
rats [3] and a delay in the development of atherosclerosis in animals kept on atherogenic diet and 
chronically injected with minute concentrations of DRPs [2, 4, 9, 13]. Most recently it was 
shown that the DRPs, when used as a component of a resuscitation fluid, were able to 
significantly improve tissue perfusion and oxygenation and to reduce/prevent lethality in animals 
subjected to severe hemorrhagic shock [1, 6].   
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Figure 2-2. Effect of a single injection of DRP (PNVF) injected in a normal animal at the 
concentration of 4 µg/ml in blood. 
2.3 DRPS IN TREATMENT OF HEMORRHAGIC SHOCK 
Traumatic injury is the leading cause of death among Americans under 44 years of age [40], and 
hemorrhage and hemorrhagic shock are major causes of these deaths. Currently, treatment of 
hemorrhagic shock is based on hemorrhage control and volume expansion, including intravenous 
infusion of large volumes of crystalloid and/or colloid solutions as well as blood products. While 
these therapies are effective in restoring fluid volume, they do not adequately address the 
problem of impaired microvascular circulation caused by hemorrhagic shock [6]. Blood soluble 
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DRPs present a potential novel therapy for hemorrhagic shock which specifically addresses 
microcirculatory complications.  
In a recent study, the effects of DRPs on blood circulation were tested in anesthetized rats 
exposed to acute hemorrhagic shock [1]. The animals were acutely resuscitated either with a 
2.5% dextran solution (Control) or with the same solution containing a 5 µg/ml concentration of 
one of two blood soluble DRPs: high molecular weight (MW=3,500 kDa) polyethylene oxide 
(PEO-3500) or a DRP extracted from aloe vera (AVP). An additional group of animals was 
resuscitated with a 75 µg/ml concentration of polyethylene oxide with a molecular weight of 200 
kDa (PEO-200), which possesses no drag reducing ability. The animals were observed for two 
hours following the initiation of fluid resuscitation or until they expired. It was found that 
infusion of the DRP solutions significantly improved tissue perfusion, tissue oxygenation, and 
two-hour survival rate. The survival rate increased from 19% in the Control group and 14% in 
the PEO-200 group to 100% in the AVP and PEO-3500 groups. Furthermore, the Control and 
PEO-200 animals that survived required a three times larger volume of infused fluid to maintain 
their blood pressure than the AVP and PEO-3500 animals. This study demonstrated that blood 
soluble DRPs, when injected at very low concentrations (as low as 5 µg/ml) in animals in 
hemorrhagic shock, rapidly increased blood pressure and restored microcirculatory flow, 
resulting in increased oxygen delivery to tissues and a significant decrease in lethality.  
In another study, Macias et al. showed that resuscitation with a small volume of DRP 
solution significantly prolonged survival and reduced mortality in a rat model of lethal, volume 
controlled hemorrhagic shock  [6]. It was found that infusion of 7 ml/kg of a 50 µg/ml solution 
of AVP increased mean arterial blood pressure and whole body oxygen consumption (VCO2) 
and delayed death compared to animals resuscitated with the same volume of normal saline. 
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Moreover, McClosky et al. showed that pretreatment of rats with DRPs (PEO-1000, 25 µg/ml in 
blood) injected prior to exposing them to hemorrhagic shock preserved tissue perfusion and 
oxygenation during hemorrhagic shock and prevented development of liver tissue hypoxia [7].  
While these in vivo studies have shown that DRPs improve outcomes following severe 
hemorrhage, the mechanism of their action in the vascular system is not yet known. One 
hypothesis is based on the fact that, in small vessels (diameter less than 0.5 mm) at physiological 
conditions, RBCs migrate toward the center of the vessel leaving a cell-free plasma layer near 
the vessel wall [41]. It was hypothesized that the DRPs cause a redistribution of red blood cells 
across the vessel, reducing the size of the cell free plasma layer and attenuating the plasma 
skimming effect at vessel bifurcations [1]. The relocation of RBCs to the near wall space causes 
an increase in apparent viscosity near the walls of the microvessels. Tsai and Intaglietta showed 
that an increase in plasma viscosity during extreme hemodilution helped to maintain animal 
functional capillary density (FCD), which was proven to be a major factor of survival in 
hemorrhagic shock [42]. In this study, the high viscosity solution allowed for wall shear stress 
dependent mechanisms to maintain optimal microvascular function even at extremely low 
hematocrit. Kameneva et al. hypothesized that DRPs might maintain this microvascular function 
in a similar manner by redistributing RBCs and thus increasing near wall viscosity [1]. 
2.4 DRP DEGRADATION 
While DRPs have shown promise as a potential therapy for many pathological states including 
acute enhancement of microcirculation in diabetic animals and treatment of hemorrhagic shock, 
these polymers show a tendency to mechanically degrade over time when exposed to high stress 
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conditions. This could present a potential obstacle to clinical use of DRPs to treat chronic 
conditions such as microcirculatory impairment caused by diabetes or atherosclerosis if the drag 
reducing effect is diminished too quickly for practical use. Therefore, the degradation behavior 
of these polymers must be investigated in detail. For clinical use, it is important to know how 
quickly the polymer will degrade in order to determine how often the treatment would need to be 
given. It is also necessary to select DRPs which would degrade sufficiently slowly for chronic 
administration to be practical since DRP preparations have to be delivered via intravenous 
injections.   
DRP degradation has been intensively studied for decades [21, 22, 39, 43-51]. 
Degradation experiments have been performed in single pass turbulent flow systems [22, 45] and 
in a rotating disk apparatus [47]. However, the effects of red blood cells (RBCs) or similar size 
particles on dynamics of this process have not yet been identified. DRP mechanical degradation 
can be defined as the chemical process by which the activation energy for the scission of a 
polymer chain is provided by mechanical stresses on the polymer [46]. Mechanical degradation 
of DRPs can also be defined as the loss of a polymer’s drag reduction effectiveness which is not 
regained after mechanical stress is abolished [52]. High molecular weight PEOs were 
demonstrated to be the most effective drag-reducers among commonly used DRPs [22]. At the 
same time, it was shown that this class of DRPs quickly mechanically degrade in turbulent pipe 
flow causing the drag reducing effect to diminish over a short exposure time [45]. 
Polyacrylamides were shown to degrade more slowly than PEOs [22, 45]. Certain high 
molecular weight polysaccharides were found to be good drag reducers that are much more 
resistant to mechanical degradation than PEOs [21-23]. The degradation of DRPs in solutions is 
likely caused by chain scission. However, some studies have shown the drag reducing ability of 
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partially hydrolyzed PAM degrades in turbulent flow with little change in MW suggesting that 
degradation occurs at least in part due to the breakup of molecular aggregates [49, 51].    
It was shown that the effective biological half life of one DRP, polyacrylamide (Separan 
AP-30), was about 35 hours in rats [53]. Mechanical degradation is likely responsible, at least in 
part, for this loss of polymer effectiveness over time. 
2.5 MECHANISMS OF INTRAVASCULAR DRP EFFECTS 
Elucidation of the mechanism(s) underlying intravascular effects of DRPs would have both 
academic and practical significance and is essential for the future applications of DRPs. Since 
there is little turbulent flow in the vascular system (excluding the aorta) the mechanism 
responsible for the intravascular DRP effect is likely different than that of the Toms effect. 
Several hypotheses have been proposed for the intravascular DRP phenomenon.   
The initial hypothesis was that DRPs acted in the vascular system by reducing resistance 
in regions where turbulent flow may occur and enhancing fluidity of the blood [18]. However, 
there is no turbulence in blood circulation in small animals, and DRPs reduce vascular resistance 
in these animals, therefore the mechanism of the intravascular DRP effect is likely not based on 
turbulent drag reduction. 
Several in vitro studies have shown that DRPs reduce the size and delay development of 
vortices and recirculation zones at vessel bifurcations under physiologically relevant flow 
conditions [19, 20], therefore reducing resistance to flow. In in vitro studies of laminar flow in 
either a bifurcated glass channel or an elastic tube containing a stenosis, DRPs were shown to 
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reduce the tendency of eddies to form. Tube diameters in these studies ranged from 3-12 mm, 
and experiments were performed at Reynolds numbers ranging from 1 – 800.   
Another hypothesis [1] behind the increase in tissue oxygenation caused by the DRPs 
was that DRPs could increase plasma mixing efficiency in capillaries, thereby facilitating oxygen 
transport. This hypothesis, which is yet to be proven, was based on the previously published 
results of experiments which demonstrated that very viscous liquids containing a small amount 
of DRP could be efficiently mixed in a curved channel (d = 3 mm) at very low Reynolds 
numbers (Re<<1) which are similar to the conditions in the capillaries, and at relatively high 
Weissenberg numbers (Wi>1) at which an elastic instability of flow occurred [54].  
A new hypothesis proposed by Kameneva et al. [1], which was further tested in these 
studies, deals with the Fåhraeus Effect and the Fåhraeus-Lindquist Effect [41, 55, 56]. The 
Fåhraeus Effect states that, in small vessels (diameter less than 0.5 mm) at physiological 
conditions, RBCs migrate toward the center of the vessel leaving a cell-free plasma layer near 
the vessel wall [56]. The velocity of the RBCs in the core region is therefore higher than the 
mean blood velocity, and the ratio of hematocrit in the tube to feed hematocrit decreases with a 
decrease in tube size [56]. This leads to a reduction in apparent viscosity, and thus flow 
resistance, in small tubes compared to that in larger tubes (Fåhraeus-Lindquist Effect) and a 
decrease in apparent blood viscosity with decrease in tube diameter [56]. The observed decrease 
in apparent viscosity is likely caused by the Fåhraeus effect, which states that hematocrit is lower 
in smaller vessels, or by the rheological effects of uneven distribution of RBCs across the vessel 
[56]. These phenomena produce a plasma skimming effect at bifurcations, where, due to the 
migration of RBCs to the center of the vessel, a lower concentration of RBCs relative to that in 
the parent branch enters the daughter branch at a bifurcation. This leads to a reduced hematocrit 
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in smaller vessel branches and, thus, in capillaries. While the original work of Fåhraeus and 
Lindquist [41, 55, 56] states that this effect occurs in vessels with diameters < 0.3 mm, there is 
discrepancy in the literature about the diameter where this effect becomes apparent. This exact 
vessel diameter has yet to be quantitatively determined [57]. It has previously been shown that 
the Fåhraeus Effect is more prominent at lower hematocrit for a given vessel diameter [56]. The 
near wall plasma layer in arterioles presents a barrier to oxygen diffusion to tissues. While under 
normal conditions this plasma skimming is not detrimental for circulation and oxygen transport, 
in certain pathological states, such as hemorrhagic shock, it might hinder the ability of the RBCs 
to transport oxygen to the tissues. It has been shown in vitro that the addition of a minute 
concentration of DRPs to red blood cells (RBCs) flowing in a straight microchannel significantly 
reduces the size of the near-wall cell free plasma layer [1, 58] as shown in Figure 2-3. In vivo 
this may result in enhancement of oxygen transport to the tissue. In addition, this would attenuate 
the plasma skimming effect and increase intracapillary hematocrit. This decrease in plasma layer 
size would also lead to an increase in wall shear stress in the small vessels. The resulting increase 
in wall shear stress would cause the endothelial cells to release endothelial-derived relaxing 
factor comprised of nitric oxide leading to vasodilation and ultimately to a decrease in systemic 
vascular resistance [59]. Average microvascular hematocrit has been shown to increase when 
tissue perfusion is increased, and this change has been attributed to vasodilation of the arterioles 
[57].  
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Figure 2-3. The size of the near wall plasma layer in a 100 micron channel decreases with an increase 
in DRP concentration (57). 
 
Neither the Fåhraeus Effect nor the drag reducing polymer effect is completely 
understood. These two phenomena have nothing in common, but may come together in the 
vascular system to produce interesting effects which have significant potential applications in 
microfluidic technology and in medicine. 
2.6 BLOOD-SOLUBLE DRAG REDUCING POLYMERS FOR POTENTIAL 
BIOMEDICAL APPLICATIONS 
Several DRPs, including PEO, PAM, and certain polysaccharides [1-14, 16, 17, 38] have been 
applied and have shown beneficial effects in animal models. High molecular weight PEOs, 
PAMs, and plant-derived polysaccharides are the most effective water soluble DRPs. The 
polymers significantly reduce resistance to turbulent pipe flow and were found to produce 
Figure 7
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beneficial effects on blood circulation. PEO, however, mechanically degrades when exposed to 
turbulent flow or other high shear stress conditions even for relatively short exposure times [45]. 
PAMs, on the other hand, are much more resistant to mechanical degradation, but their apparent 
toxicity presents problems for potential biomedical use [9, 12]. Plant-derived DRPs are highly 
resistant to mechanical degradation [22-24] and many polysaccharides are non-toxic [24, 25]. 
However, they are not well characterized and often difficult to manufacture in industrial 
quantities. Therefore, the search continues for a DRP which produces beneficial effects on blood 
flow, and is well characterized, biocompatible, resistant to mechanical degradation and easy to 
manufacture.   
Three candidates for DRP that could meet these requirements are a natural polymer 
derived from the aloe vera plant (AVP), high molecular weight poly(N-vinylformamide) 
(PNVF), which is synthesized from a non-toxic isomer of acrylamide, and hyaluronic acid, a 
polysaccharide produced in the cellular plasma of vertebrates as well as by certain bacteria. 
2.6.1 Aloe vera derived DRP 
High molecular weight polysaccharides, such as a polymer extracted from okra and characterized 
as a rhamnogalactogalacturonan, have been shown to be effective drag reducing polymers which 
produced beneficial hemodynamic effects in a rodent model [17]. It was first discovered by 
Gowda [60, 61] that high molecular weight polysaccharides could be isolated from aloe plants 
via alcohol extraction. An aloe based polysaccharide would be an attractive DRP for biomedical 
applications since toxicological studies have shown that Acemannan, a product extracted from 
the aloe leaf gel, has minimal systemic toxicity when injected intraperitoneally or intravenously  
[24]. Recently, it was discovered that a polymer extracted from the aloe vera plant mucilage was 
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also a very effective drag-reducer [1, 34, 62]. The aloe vera leaf consists of three major 
components: clear sheets comprised of cell walls and membranes, microparticles comprised of 
degenerated cellular organelles, and a viscous liquid gel comprised of the liquid components of 
mesophyll cells. The DRP is extracted from the viscous gel portion of the aloe with ethanol. It is 
known that the ethanol insoluble portion of the gel is > 50% carbohydrate [63]. A mannan 
component has been identified in this portion of all aloe species studied, although differences in 
molecular weight, degree of acetylation, and mannose-glucose ratio have been observed [60, 63]. 
In one study, the polysaccharides found in the aloe vera gel have been characterized as at least 
four different partially acetylated linear glucomannans which contain 1-4 glycosidic linkages 
[64]. In another study, the polysaccharides in aloe vera were shown to be composed of β-(1,4)-
linked acetylated polymannans containing O-acetyl groups with a mannose monomer to acetyl 
ratio of approximately 1:1 [24]. A structure for the major component of aloe vera gel was 
proposed by Chow et al. [60] based on data from chromatography, carbohydrate compositional 
analysis, linkage analysis and NMR. This structure consists of a linear β-1,4-linked mannose 
backbone with β-1,4-linked glucose substituting for mannose approximately every 30 residues. 
Mannose residues are acetylated at O2, O3 or O6 and sidechains are single galactose residues α-
1,6-linked to the mannoses residues in the backbone. This proposed structure is shown in Figure 
2-4. However, the structure of the active drag reducing component of the aloe vera DRP remains 
unknown. 
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Figure 2-4. Proposed structure of the major component of aloe vera gel [60] 
 
2.6.2 Poly(N-vinylformamide) 
Water-soluble PNVF has been known for the past 40 years but has become more common in the 
last decade due to the development of improved processes for synthesis and purification of the 
N-vinylformamide (NVF) monomer as well as the growing uses for PNVF and its derivatives in 
industrial applications [65]. The polymer has been considered as a replacement for toxic 
acrylamide polymers for industrial use [66]. Applications for PNVF and its hydrolysis products 
include water treatment, papermaking, production of textiles, personal care items, adhesives and 
coatings, and use in oil field industry and as a rheology modifier [67]. PNVF, shown in Figure 2-
5, is synthesized from the NVF monomer, which is a highly reactive isomer of acrylamide with 
low toxicity [67]. It was shown that very high molecular weight PNVF (6.7x106 Da) could be 
synthesized using an inverse emulsion technique [68]. Due to its similarities with PAM, a well-
known very effective DRP, its ease of polymerization [68], and its high solubility in water [67], 
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high molecular weight PNVF could be a good candidate for a DRP. The low toxicity of the NVF 
monomer [67] provides motivation for testing PNVF as a potential DRP for biomedical use. 
Although hydrolysis products of PNVF, including poly(vinyl amine), have been tested and 
shown to be effective DRPs [69], the drag reducing ability of PNVF was never tested before. 
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Figure 2-5. Structure of PNVF 
2.6.3 Hyaluronic Acid 
Hyaluronic acid (HA), also referred to as hyaluronan since it primarily exists in its polyanion 
form and not as the free acid form, is a linear, unbranched, negatively charged polysaccharide 
with a molecular weight ranging from 105 to 107 Da. It is comprised of alternating units of D-
glucuronic acid and N-acetyl-D-glucosamine. The structure of HA is shown in Figure 2-6. It is 
synthesized in the cellular plasma and found in all tissues and body fluids of vertebrates and also 
in certain bacteria. HA was first discovered by Meyer and Palmer in 1934 [70]. Its medical 
applications include wound care, medical device coating, orthopedic and ophthalmic 
applications, and use as a drug-delivery vehicle [71]. One of the most successful applications of 
HA in the medical field is in treating osteoarthritis [70]. HA was previously shown to have drag 
reducing ability [72], and its current FDA approval for certain biomedical applications [73] 
makes it an ideal candidate to be applied for enhancement of blood circulation.  
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Figure 2-6. Structure of hyaluronic acid 
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3.0  HYDRODYNAMIC, RHEOLOGICAL, AND MOLECULAR TESTS TO 
CHARACTERIZE BLOOD SOLUBLE DRAG REDUCING POLYMERS 
In order to help to choose DRPs for potential clinical use, a standard set of tests was developed 
for their characterization and evaluation of efficacy. It has previously been shown that polymers 
which are effective at reducing resistance to turbulent flow in vitro are most effective in 
improving hemodynamics in vivo. It is also known that high molecular weight, linear structure, 
and non-Newtonian behavior of concentrated solution are characteristics of effective DRPs [26]. 
Therefore, methods were developed to evaluate these properties and predict a polymer’s 
likelihood to be a good DRP for biomedical use. Microscale methods were also developed as a 
next step in the prediction of whether a DRP would be effective in improving blood flow in vivo. 
These methods involve the study of RBC flow in microchannels and will be discussed in detail in 
Specific Aim 2. In addition, it is important to ensure that the DRPs maintain their activity in the 
presence of flowing RBCs. Test methods were also developed to assess mechanical degradation 
of these polymers in order to compare relative stability of DRPs and potentially gauge how long 
the DRPs could be effective in the body. Since PEO is known to be one of the most effective of 
the commonly used DRPs [22] and is commercially available at several molecular weights, and 
dextran is known to be a high molecular weight polymer which has no drag reducing properties, 
PEOs and dextran were used to assess the reliability of the tests developed in this specific aim. 
Several PEOs, PEO-5000 (MW = 5000 kDa, Aldrich Chemical), PEO-4500 (MW = 4500 kDa, 
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Polyox WSR-301, Dow Chemical), PEO-2000 (MW = 2000 kDa, Aldrich Chemical), PEO-1000 
(MW = 1000 kDa, Aldrich Chemical), PEO-600 (MW = 600 kDa, Aldrich Chemical), and PEO-
200 (MW = 200 kDa, Aldrich Chemical), were used for these studies. 
3.1 METHODS 
3.1.1 Polymer drag reduction in turbulent flow 
The Toms effect is known to occur only in developed turbulent flow. Therefore the first test 
system to identify candidate polymers was developed with the capacity to run at sufficiently high 
Reynolds numbers. This recirculating flow system for testing the turbulent flow drag reducing 
ability of polymers consists of a centrifugal pump (BioMedicus, Inc.), a flow meter and clamp-
on flow probe (Transonic Systems, Inc.), a pressure transducer (PCB Piezotronics, Inc.), a 
smooth glass resistive tube with known dimensions (either 0.44 cm ID, 91.5 cm length or 0.56 
cm ID, 120 cm length), and a one liter open fluid reservoir connected with 3/8 inch Tygon tubing 
(Cole-Parmer). A schematic of the system is shown in Figure 3-1. Flow rates and system 
geometry were chosen based on criteria necessary for the assessment of the drag reducing 
phenomenon. Entrance length, le, calculated using 
dl e ⋅⋅= 6
1
Re4.4                                                                                            (1) 
where d = tube diameter and Re = tube Reynolds number, is ~10% of the tube length [74]. DRP 
was added to circulating saline to give concentrations ranging from 1 to 500 µg/ml in solution. 
Saline was chosen as a testing vehicle (vs. water) since the ultimate goal of this study was to 
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bring DRPs to the animal test point and since some of DRPs have significantly different 
physicochemical properties when dissolved in saline vs. water. Pressures and flow rates were 
recorded before and after DRP addition. The in vitro flow experiments were performed at room 
temperature. Drag reduction at a constant flow rate was calculated using  
100
0
0 ⋅∆
∆−∆=
P
PP
DR p                                                                                      (2)  
where DR = drag reduction (%), ∆PP = pressure drop for polymer solution, and ∆P0 = pressure 
drop for saline alone. This formula, which represents a simple percent error, was chosen to 
quantify drag reduction since it is the most commonly used metric in DRP literature. This 
generally accepted definition of drag reduction was provided by Savins in the 1960s [26, 32]. 
Reynolds number (Re) was calculated using the formula [74] 
νπ ⋅⋅
⋅=
d
Q4Re ,                                                                                                  (3) 
where Q = volumetric flow rate, d = tube diameter and ν = kinematic viscosity. A dimensionless 
friction factor, λ, was calculated for the DRP solutions and compared to that of saline alone using 
[74] 
2
25
8 Ql
Pd
⋅⋅⋅
∆⋅⋅= ρ
πλ ,                                                                                             (4)   
which is derived from the Darcy-Weisbach equation, where λ = friction coefficient, ρ = density 
of the fluid, and P = the pressure drop along the tube length, l. Blasius friction factor for 
turbulent flow was also calculated using the Equation 5 [74], 
 25.0Re
316.0=λ                     (5) 
and used for comparison to the experimental data.  
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Drag reducing effectiveness of several PEOs, PEO-5000, PEO-4500 PEO-2000, PEO-
1000, PEO-600, and PEO-200, was determined. Results for experimental data are presented as 
mean friction factor ± standard deviation. Mean friction factors were compared using one-way 
ANOVA followed by unpaired, two-sample Student’s t-tests assuming unequal variances. 
Although blood flow in the body is not turbulent and the mechanism of the DRPs in the 
circulatory system most likely differs from that in turbulent flow, previous studies have shown 
that the DRPs that provide the highest drag reduction in turbulent flow also have the greatest 
beneficial effects on blood circulation. On the other hand, polymers which do not produce drag 
reduction are not effective in vivo. Therefore, the DRPs which give the best drag reducing ability 
were determined using the turbulent flow test system, and these DRPs were used to perform 
microchannel studies in order to evaluate their effectiveness in more physiologically relevant 
conditions and elucidate the mechanism responsible for the intravascular DRP phenomenon as 
well as to perform in vivo tests. 
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Figure 3-1. Schematic for turbulent flow system used to test DRP efficacy 
 
3.1.2 Polymer drag reduction in turbulent flow of blood 
The efficacy DRPs in turbulent blood flow was tested using the circulating system described in 
3.1.1 with blood replacing saline as the test fluid. This allowed for the assessment of the DRPs 
performance in the presence of RBCs, which is important since DRPs injected intravenously 
contact blood cells in vivo. It was therefore important to ensure that RBCs were not detrimental 
to the DRPs’ activity.  
Bovine blood obtained from a local slaughterhouse and diluted to the desired hematocrit 
of 20% with saline was used for these tests. The drag reducing efficiency of two DRPs, PEO-
4500 and an aloe based DRP (AVP), was studied at concentrations ranging from 10 to 100 µg/ml 
 27 
using the methods described in 3.1.1. Reynolds numbers for these studies of turbulent blood flow 
ranged from 5,000 to 10,000. Results are presented as average drag reduction ± standard 
deviation at each tested flow rate (Reynolds number).  
3.1.3 Gel Permeation Chromatography (GPC) 
Molecular characteristics, including high molecular weight and linear structure are important in 
determining a DRP’s potential drag reducing efficiency. Number average and weight average 
molecular weights (Mn and Mw), intrinsic viscosity (IV), radius of gyration (Rg), hydrodynamic 
radius (Rh), and polydispersity index (PDI) were measured using a Viscotek Triple Detector 
Array gel permeation chromatography (GPC) system (Viscotek, Houston, TX).  
Mn is defined as the summation of the mole fraction of each species multiplied by its 
molecular weight and is sensitive toward molecules of relatively low molecular weight (<104 to 
5x105). It can be determined through methods such as end group analysis, membrane osmometry, 
and vapor pressure osmometry. Mw is defined as the summation of the weight fraction of each 
species multiplied by its molecular weight. It is more sensitive to molecules of average 
molecular weight (5x105 to 107). It can be calculated by light scattering and ultracentrifugation. 
PDI is defined as Mw/Mn and describes the MW distribution of a polymer [75]. Another average 
molecular weight, z average (Mz), is a higher order molecular weight which is sensitive to 
molecules of high molecular weight. IV, defined as specific viscosity divided by concentration 
and extrapolated to zero concentration, is used to describe the hydrodynamic size of a particular 
polymer. Its units are volume per mass (dl/g), and it is proportional to the hydrodynamic volume 
of one gram of polymer. Rh can be calculated from the hydrodynamic volume of the polymer 
molecule, determined from intrinsic viscosity. Rh calculation assumes the molecule to be 
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spherical in shape. Rg calculation, on the other hand, takes into account the fact that most 
polymers are actually random coils, not hard spheres as assumed in Rh calculations. Rg is 
determined through light scattering and viscometry.  
Separation was performed on a methacrylate-based column with an exclusion limit of 
5x107 Da. The system combines a refractive index detector, a right angle laser light scattering 
detector, and a differential viscometer in order to determine average MWs (Mn and Mw), IV, Rg, 
Rh, and molecular weight distribution in a single experiment. Column and detector temperatures 
were maintained at 30ºC and the mobile phase was 0.1 M NaNO3 with 0.01% NaN3. The system 
was calibrated using a PEO standard with a molecular weight of 22 kDa and a narrow molecular 
weight distribution (PDI ~ 1.0). Results are presented as mean ± standard deviation. 
3.1.4 Rheological Characterization 
Rheological parameters such as viscosity, elasticity, and relaxation time also can be analyzed in 
order to fully characterize DRPs since these polymers are known to have high viscosity and 
elasticity in relatively concentrated solutions. These DRP solutions are also known to exhibit 
non-Newtonian flow behavior. A non-Newtonian fluid is defined as a fluid in which viscosity 
depends on shear strain rate. Due to the non-Newtonian nature of concentrated DRP solutions, it 
is advantageous to measure rheological properties over a wide range of shear rates. This was 
accomplished using a Brookfield cone and plate rotational rheometer (Middleboro, MA) as well 
as a Vilastic 3 viscoelasticity analyzer (Austin, TX). The Vilastic 3 employs controlled 
oscillatory flow in a cylindrical tube to measure the major rheological parameters including 
viscosity, elasticity, and relaxation time.  
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Viscosity is defined as a measure of resistance of a material to flow, and elasticity can be 
defined as the ability of a material to return to its original state following deformation caused by 
applied stress. Relaxation time is the time necessary for a system to forget the configuration it 
had prior to a perturbation [76]. 
Mean values of each rheological parameter ± standard deviation were plotted as a 
function of shear rate. Rheological parameters were measured in solutions with a concentration 
of 2.5 mg/ml in saline. Asymptotic viscosity of DRP solutions at a concentration of 100 µg/ml 
was measured using a capillary viscometer (Cannon Manning). At this concentration, the DRP 
solutions behave as Newtonian fluids, and therefore measurement of asymptotic viscosity is 
sufficient for rheological characterization. 
3.1.5 DRP Degradation Studies 
DRPs, especially PEO, were shown to produce strong beneficial effects on blood circulation with 
a considerable potential for clinical applications, but quickly mechanically degrade when 
exposed to turbulent flow or other relatively high shear stress conditions even for relatively short 
exposure times [45]. For practical use, it is important to understand the degradation behavior of 
the DRPs. Although there is almost no turbulent flow in the body, degradation studies were 
performed in turbulent flow since it provides the shear stresses necessary to compare degradation 
of different DRPs in a relatively short time period and allowed for measurement of polymer 
degradation via decline of their drag reducing ability. The circulating flow system described in 
3.1.1 was also used to study mechanical degradation of DRPs in turbulent flow. A decrease in a 
polymer’s ability to reduce resistance to flow, signified by a decrease in flow rate at fixed wall 
shear stress, indicated mechanical degradation of the polymer. Turbulent flow degradation 
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studies also allowed for comparison with literature since most previous studies were performed 
in turbulent flow. Wall shear stress in the resistive tube was held constant at 45 N/m2 throughout 
the degradation experiments. While shear stresses in the arteries of a healthy human range from 1 
to 10 N/m2 [77], arteries with stenosis can have shear stresses greater than 10 N/m2 [78], and 
shear stress in artificial heart valves and blood pumps can reach greater than 100 N/m2 [78]. 
Reynolds numbers (based on the diameter of the glass tube) ranged from 10,000 – 27,000. 
Baseline pressure and flow rate were recorded before polymer addition, and DRP was added to 
the system at a concentration of 0.1, 0.25, or 0.5 mg/ml. Pressure and flow were monitored 
throughout a five-hour period or until the DRP ceased to produce any effect. Drag reduction at 
constant wall shear stress (and therefore constant pressure drop) was calculated for each time 
point using        
100
0
0 ×−=
Q
QQDR P                                                                                              (6) 
where QP = flow rate of polymer solution and Q0 = flow rate of saline alone. Results are 
presented as mean drag reduction ± standard deviation. The degradation behavior of several 
PEOs including PEO-4500, PEO-2000, PEO-1000, PAM (Praestol 2510, Stockhausen, Inc.), 
PNVF, and HA was studied. 
 GPC, as described in 3.1.3 was used to monitor MW (Mn, Mw, Mz), IV, Rg, and PDI 
during exposure to flow. Mz is the z average molecular weight, which is sensitive to molecules in 
the high end of the MW distribution. Polymer chain scission was signified by a decrease in 
average MW and/or a shift in the MW distribution. The effects of exposure to flow, and therefore 
mechanical degradation, on PDI were carefully examined. Chain scission and break up of 
aggregates have both been shown to contribute to DRP degradation [49, 51]. A significant 
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change in MW and MW distribution with loss in drag reducing ability would show that the 
primary cause is chain scission. No significant change in MW distribution would occur if the 
major factor is break up of aggregates.  
Additionally, the degradation of DRPs in the presence of RBCs or rigid particles was 
investigated. This study was motivated by the fact that no previously published work was found 
on the effect of the presence of particles in DRP solutions on degradation of DRPs. Moreover, 
because DRPs only affect hemodynamics when they are injected intravenously, it is an important 
consideration for potential clinical use. Bovine blood was obtained from a local slaughterhouse 
and centrifuged for 15 minutes at 3600 rpm to remove plasma and buffy coat which consisted of 
platelets and white blood cells. The RBCs were resuspended in saline at a concentration of 5, 10, 
or 20%. A rigid particle suspension was prepared by adding glass particles (Potters Industries 
Inc., one to one mixture of 110P8 and 60P18 with mean diameters of 11 and 18 µm and densities 
of 1.1 g/cm3 and 0.6 g/cm3 respectively) to saline at a concentration of either 1 or 5% by volume. 
The degradation behavior of two DRPs, PEO-4500 and AVP, was investigated in the presence of 
RBCs, and that of PEO-4500 was also tested in the presence of rigid particles. Additionally, 
PEO-4500 degradation was tested in a 15% glycerol solution, prepared as a viscosity analog for 
the 20% RBC suspension. The viscosity of the 20% RBC suspension was measured to be ~ 1.8 
cP using a capillary viscometer (Cannon Manning) at a shear rate of ~ 600 s-1. Therefore, a 15% 
glycerol solution (~1.7 cP) was prepared as an equiviscous analog for the 20% RBC suspension 
to determine whether the effects of particles on degradation were due to the particles themselves 
or to the increase in viscosity.      
In order to quantitatively compare the degradation behavior between two DRPs or 
between DRPs in the presence or absence of particles, the mechanical degradation behavior of 
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DRPs in the turbulent flow system, both in saline solution and in the presence of RBCs or rigid 
particles, was examined by fitting it to a previously developed single relaxation decay model [44, 
46] as 
 )*exp(
)0(
)( tk
DR
tDR −=                                                                                         (7)                                          
where t is exposure time of the polymer to flow, DR(0) and DR(t) are drag reduction at time 0 
and t respectively, and k, while not a true rate constant, is a property that quantifies rate of loss of 
drag reducing activity. 
3.2 RESULTS 
A comprehensive set of hydrodynamic, rheological, and molecular tests for the characterization 
and evaluation of blood soluble drag reducing polymers, which have potential for clinical use, 
was developed. The tests were performed on various PEOs, which ranged in molecular weight 
from 2 x 105 – 5 x 106 Da in order to show that the these tests could be effectively used to 
characterize new DRPs. The tests were also performed on high MW dextran (Aldrich, MW 
claimed by manufacturer = 2,000 – 40,000 kDa), which is known to be highly branched and 
therefore not a drag reducer, as a negative control. 
3.2.1 Polymer drag reduction in turbulent flow 
The drag reducing properties of PEOs and a high MW dextran were characterized using the 
turbulent flow system described in section 3.1.1. It was found that drag reduction (DR) produced 
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by PEOs increased with an increase in MW, and that, as expected, dextran exhibited no DR. 
Friction factor for saline agreed well with values calculated using the Blasius equation, whereas 
the friction factors for PEOs with MW above 1000 kDa were much lower than the those 
calculated using the Blasius equation. All of the tested PEOs, with the exception of PEO-200, 
produced a statistically significant reduction in friction compared to saline (control) over the 
entire range of studied Reynolds numbers (p < 0.01). Figure 3-2 shows dimensionless friction 
factor vs. Re for PEO when added to the circulating system at 100 µg/ml, and Table 3-1 shows 
the average DR produced by each polymer.   
These tests were used in this project to characterize and evaluate the potential of new 
DRPs to be effective in blood circulation. Results of these studies are discussed in Section 5. 
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Figure 3-2. Friction factor vs. Re for several PEOs tested in a turbulent flow circulating system at 
100 µg/ml. The drag reducing ability of PEO increased with an increase in MW of the PEO 
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Table 3-1. Average drag reduction produced by various PEOs at a Reynolds number of 23,000 
MW Drag Reduction  
(Da)  at 100 µg/ml (%)
200K 0 
600K 15 
1000K 22 
2000K 29 
4500K 34 
5000K 38 
Dextran 2-
40million 0 
 
3.2.2 Polymer drag reduction in turbulent flow of blood  
The efficacy of DRPs in turbulent blood flow was investigated using the flow system described 
in 3.1.1. Bovine blood obtained from a slaughterhouse and diluted with saline to a hematocrit of 
20% was used for this study. Two DRPs, PEO-4500 and aloe derived DRP (AVP), were tested, 
and both were found to be able to significantly reduce flow resistance in blood. Figure 3-3 shows 
the drag reduction produced by these polymers in turbulent blood flow [79]. As one can see, 
aloe-based DRP has much higher drag-reducing efficiency than PEO-4500 when compared at the 
same concentrations. Since the viscosity of blood was significantly higher than that of water, the 
Reynolds numbers obtained in the blood loop were lower than those in the saline loop and, 
therefore, the drag reducing effect in blood was not as strong as that in saline. It is known that 
drag reducing ability increases with increased Reynolds number [27].  
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Figure 3-3. Maximum drag reduction in turbulent flow of blood produced by PEO-4500 and AVP at 
various concentrations.  
3.2.3 GPC 
Molecular characteristics, including Mn, Mw, IV, Rg, Rh, and PDI were determined for several 
different PEOs and for high MW dextran. Results, obtained by GPC and presented as mean ± 
standard deviation, are shown in Table 3-2. 
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Table 3-2. Molecular characteristics of PEO and dextran obtained using GPC. 
  Mn Mw IV Rg Rh PDI 
  (Da) (Da) (dl/g) (nm) (nm)   
PEO-200 4.0x104 ± .3x104 2.0x105 ± .02x105 1.6 ± .01 20.0 ± .1 15.4 ± .1 5.1 ± .3 
PEO-600 2.1x105 ± .2x105 9.5x105 ± .3x105 5.0 ± .06 50.3 ± 1.2 38.7 ± .6 4.5 ± .3 
PEO-1000 5.1x105 ± 1.0x105 1.5x106 ± .2x106 6.8 ± .4 65.3 ± 4.0 50.7 ± 2.9 3.0 ± .3 
PEO-2000 5.3x105 ± 1.5x105 1.9x106 ± .8x106 8.6 ± .4 77.7 ± 1.5 60.0 ± 1.0 3.1 ± .2 
PEO-4500 2.8 x106± .6x106 4.4x106± .2x106 13.0 ± .5 120.1 ± 3.6 92.1 ± 3.1 1.7 ± .4 
PEO-5000 2.0x106 ± .4x106 3.0x106 ± .3x106 12.7 ± .7 107.3 ± 5.5 82.3 ± 4.5 1.6 ± .2 
Dextran 6.8x106 ± .3x106 1.4x107 ± .09x107 0.9 ± .06 73.2 ± 1.5 56.3 ± .6 2.0 ± .1 
 
3.2.4 Rheological Characterization 
Concentrated PEO solutions with MW above 1 x 106 Da exhibited non-Newtonian behavior, a 
well-known property of DRPs. Viscosity vs. shear rate curves for these solutions at a 
concentration of 2.5 mg/ml, determined using a cone and plate viscometer, are shown in Figure 
3-4. Viscosity, elasticity, and relaxation time vs. shear rate curves for the PEO solutions with 
MW 1 x 106 Da and greater are shown in Figures 3-5, 3-6, and 3-7. Elasticity and relaxation time 
are negligible for the lower MW PEOs and are therefore shown only for the two tested PEOs 
with the highest MW (PEO-4500 and PEO-2000). PEOs with MW below 1 x 106 Da, however, 
behaved as Newtonian fluids. PEO-200 and PEO-600 had viscosities of 1.4 and 1.8 cP at 2.5 
mg/ml, respectively. Asymptotic viscosities at a concentration  of  0.1 mg/ml were measured 
using a capillary viscometer at 22°C ± 1°C and are shown in Table 3-3. At low concentrations, 
the DRPs behave as Newtonian fluids where viscosity is independent of shear rate. Therefore it 
is valid to use asymptotic viscosity in characterizing these polymer solutions. 
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Figure 3-4. Viscosity data for PEOs at 2.5 mg/ml measured using a Brookfield cone and plate 
rheometer 
 
 38 
110
100
0 100 200 300 400 500 600 700 800
Shear rate (1/s)
V
isc
os
ity
 (c
P)
PEO-1000 PEO-2000 PEO-4500
 
Figure 3-5. Viscosity data for PEOs at 2.5 mg/ml obtained using a viscoelastometer (Vilastic) 
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Figure 3-6. Elasticity data for PEOs at 2.5 mg/ml obtained using a viscoelastometer (Vilastic) 
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Figure 3-7. Relaxation times for PEOs at 2.5 mg/ml obtained using a viscoelastometer (Vilastic) 
 
 
Table 3-3. Asymptotic viscosities of PEOs measured by a capillary viscometer at a concentration of 
0.1 mg/ml at 22 °C ± 1 °C. 
  Capillary Viscosity (cP) 
   at 0.1 mg/ml 
PEO-200 1.08 
PEO-600 1.10 
PEO-1000 1.10 
PEO-2000 1.22 
PEO-4500 1.25 
Dextran 1.07 
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3.2.5 DRP Degradation Studies 
PEO-4500 initially produced a significant reduction in resistance to flow of saline and of RBC 
suspensions when it was added to flowing fluid. However, the drag reducing efficiency of this 
polymer decreased rapidly with increased time of exposure to flow. In saline, the PEO-4500 
completely lost its drag reducing ability after about an hour of flow. The presence of RBCs, 
however, significantly accelerated the polymer degradation rate, as shown in Figure 3-8. 
Additionally, an increase in RBC concentration led to an increase in degradation rate. In a 20% 
suspension of RBCs, the PEO-4500 completely lost its drag reducing effectiveness in three 
minutes (compared to ~60 minutes in saline alone).   
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Figure 3-8. Drag reduction vs. time for PEO-4500 at a concentration of 0.1 mg/ml in saline and in the 
presence of RBCs at several concentrations. The rate of DRP degradation increases with an increase in RBC 
concentration 
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  A similar effect was observed for PEO-4500 degradation in suspensions of rigid glass 
particles. Polymer degradation rate increased with an increase in particle concentration (Figure 
3-9). While the polymer degraded much faster in either type of suspension than in saline, rigid 
particles caused a greater increase in PEO-4500 degradation rate than deformable RBCs at the 
same concentration (Figure 3-10). The matching viscosity control tests showed that while PEO-
4500 degraded slightly faster in a 15% glycerol solution than in saline, the degradation was 
significantly slower in glycerol than in the 20% RBCs, which had the same viscosity (Figure 3-
11). 
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Figure 3-9. Drag reduction vs. time for PEO-4500 at a concentration of 0.1 mg/ml in saline and in the 
presence of rigid glass particles at two concentrations. The rate of PEO degradation increases with an 
increase in concentration of particles. 
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Figure 3-10. Drag reduction vs. time for PEO-4500 at a concentration of 0.1 mg/ml in saline 
compared to that in 5% RBCs or 5% rigid glass particles. The rate of polymer degradation is higher in a 
RBC suspension than in saline, and further increases in a suspension of rigid particles. 
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Figure 3-11. Drag reduction vs. time for PEO-4500 at a concentration of 0.1 mg/ml in saline 
compared to that in a 20% RBC suspension and an equiviscous glycerol solution. The rate of degradation of 
PEO-4500 at 0.1mg/ml in a 15% glycerol solution, having the same viscosity as a 20% RBC solution is slightly 
higher than in saline, but much lower than in the 20% RBC suspension 
 
The MW of PEO-4500, determined by GPC, decreased significantly with increased 
exposure to flow. Mw of the PEO-4500 was initially 4.4 x 106 Da, but decreased to 2.5 x 106 Da 
within one hour and 1.5 x 106 Da following five hours of exposure to turbulent flow in saline. It 
is known that, as DRPs decrease in molecular weight, the onset of drag reduction occurs at 
higher Reynolds numbers [27]. Therefore, although polymers with molecular weights above 106 
Da can still produce drag reduction, the Reynolds number in this case may not be high enough 
for the PEO with a molecular weight of 2.5 x 106 Da to produce significant drag reduction. IV 
also decreased significantly throughout the five hour study. IV of PEO was initially 9.8 dl/g but 
decreased to 7.7 dl/g within one hour and to 5.8 dl/g in five hours. The initial measurements for 
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this study were taken after one minute of exposure to turbulent flow. Although this initial Mw is 
similar to that given for undegraded PEO-4500 in Table 3-2, the PDI is much higher in this case. 
Therefore, there is a larger fraction of low MW polymer which would account for the lower IV 
and Rg. The discrepancy between the initial values of the molecular parameters measured in this 
study and the values in Table 3-2 may be due to the fact some degradation likely occurred during 
the first minute of exposure to flow. The molecular characteristics of PEO-4500 following 
exposure to turbulent flow in saline for a series of times are shown in Table 3-4.   
 
Table 3-4. Molecular characteristics and drag reduction (DR) of PEO-4500 at 0.1 mg/ml during 
turbulent flow degradation in saline 
Time Mw IV Rg PDI DR 
(min) (Da) (dl/g) (nm)  (%) 
1 4.4 x 106 9.8 101 3.4 34 
5 3.7 x 106 9.4 95 3.5 28 
15 3.2 x 106 8.6 88 3.6 17 
30 2.8 x 106 8.1 84 3.1 8 
60 2.5 x 106 7.7 80 2.9 3 
120 2.0 x 106 6.9 72 2.9 1 
180 1.8 x 106 6.3 67 3 0 
240 1.7 x 106 6.2 66 2.5 0 
300 1.5 x 106 5.8 63 2.7 0 
 
The single relaxation decay model, described in Section 3.1.5, fit the data well for PEO 
degradation in any of the tested solutions or suspensions (saline, RBCs, rigid particles, glycerol) 
for short term exposure to flow. DRP degradation rate (k) increased linearly with an increase in 
particle concentration as seen in Figure 3-12.  
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Figure 3-12. The rate of PEO degradation rate increases linearly with an increase in particle 
concentration. Rigid particles cause a larger increase in degradation rate than flexible RBCs for a given 
concentration increase. 
3.3 DISCUSSION 
As described in sections 3.1.1 – 3.1.4 and 3.2.1 – 3.2.4, a series of tests was created to 
characterize and evaluate the effectiveness of a polymer as a DRP, and the test protocol was 
validated using well characterized polymers, PEOs and high MW dextran. The results obtained 
in this specific aim for a well known DRP, PEO, and a high molecular weight polymer which is 
not a drag reducer, high MW dextran, agreed well with the literature. These tests verified that 
high molecular weight in combination with linear structure and non-Newtonian behavior in 
relatively concentrated solution are essential for drag reduction and that these properties could be 
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accurately evaluated using the protocol developed in this aim. Evaluation of DRP efficacy in 
turbulent blood flow showed that the presence of RBCs, which would be encountered in vivo, 
does not prevent the studied DRPs from reducing flow resistance. This test could be used to 
ensure that the effectiveness of newly developed DRPs would not be destroyed by RBCs. 
Overall, this series of experiments could be applied to new polymers to determine their potential 
to be used as DRPs for biomedical applications. One limitation of this test protocol is that, since 
the mechanism of the intravascular DRP effect is likely different from that in turbulent flow, 
proving that a DRP is effective in turbulent flow may not be enough to ensure that it will be 
effective in vivo. However, considering that the PEOs described above were tested in animal 
models, and there was a certain correlation found between intravascular effectiveness of these 
polymers and their physicochemical characteristics including drag reducing ability, it can be 
concluded that the developed set of tests is predictive for the in vivo behavior of new DRP 
candidates. This concern will be addressed more thoroughly in Specific Aims 2 and 3.   
Mechanical degradation studies of DRPs, described in section 3.1.5 and 3.2.5, are also 
essential in characterizing DRPs as well as predicting their potential for use in vivo, especially in 
treating chronic circulatory disorders such as atherosclerosis or complications of diabetes. 
Determination of degradation behavior in the presence of particles such as RBCs is especially 
useful in predicting how DRPs will behave in the body, specifically how quickly their effects 
will diminish and therefore how often they may have to be administered. The observed increase 
in degradation rate of PEO in the presence of particles is a concern that must be considered in 
choosing DRPs for use in vivo.  
The results discussed in Section 3.2.5 suggested that the increased degradation in 
suspensions is likely due to the combination of increased viscosity and the presence of particles, 
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with the particles playing the larger role. It has been shown that the intensity of turbulence of 
blood at hematocrits lower than 30% is greater than that of plasma adjusted to the same viscosity 
at a given Reynolds number [80]. Collisions between cells and their tumbling result in changes 
of direction of motion and, thus, the development of additional vortices. These vortices might be 
responsible, at least in part, for the increased PEO degradation rate observed in the presence of 
particles. Rigid RBCs are known to increase turbulence intensity even more than normal, flexible 
cells. The deformation of RBCs may absorb some of the kinetic energy from the turbulent flow 
and therefore reduce the size of these vortices to some extent [80]. This may explain the increase 
in PEO degradation rate in the presence of rigid particles compared to that in deformable RBCs.  
The developed test provides a useful method for comparing the degradation behavior of 
various DRPs or a DRP in different solvents. Contribution of the shear stresses in the pump head 
to the mechanical degradation of PEO should be considered in the future in order to 
quantitatively determine the stresses which cause DRP degradation, but does not play a major 
role in this comparative study since the studies were performed at the same pump speed. It has 
been suggested that mechanical degradation of DRPs could be used as a model to study shear 
induced RBC damage [81]. It was also shown in an in vitro study that the Biomedicus pump did 
not produce significant hemolysis [82], and therefore it can be hypothesized that the major DRP 
degradation did not occur in the pump. 
A single relaxation decay model was effective in predicting degradation behavior of PEO 
in all tested suspensions. Rate constant increased linearly with an increase in particle 
concentration, and was much higher for rigid particles than for deformable RBCs. This model 
could be applied to predict the time course of degradation of PEO. This has little practical use for 
PEO, however, since PEO degradation, especially in suspensions, occurs very quickly and can be 
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easily studied experimentally. A similar model was considered for predicting the mechanical 
degradation of other DRPs which degrade much more slowly. This is discussed in section 
5.2.1.5. 
Overall, the methods devised in this aim provided a strong basis for characterization of 
DRPs and determination of their efficacy. The combination of these tests can be used to evaluate 
the potential of candidate polymers to be effective in improving blood flow in the vascular 
system. 
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4.0  IN VITRO MICROSCALE STUDIES OF POTENTIAL MECHANISMS OF THE 
INTRAVASCULAR EFFECTS OF DRAG REDUCING POLYMERS 
Elucidation of the mechanisms of the DRP effects on hemodynamics is essential from a scientific 
point of view as well as for their progress toward potential clinical use. The effects of DRPs on 
blood flow over a range of macro and microflow conditions similar to those found in the vascular 
system were studied using straight tubes of various lengths and diameters as well as fabricated 
models of microvessel bifurcations. In this specific aim, microchannel flow systems simulating 
the microflow environment of RBCs encountered in small arteries, arterioles and capillaries were 
designed and fabricated. The effects of DRPs on blood microflow were quantified using pressure 
and flow measurements as well as blood hematocrit measurements and microscopic flow 
visualization methods. 
4.1 METHODS 
4.1.1 Microchannel fabrication 
Standard photolithography techniques and replica molding were used to fabricate bifurcated 
microchannels. Systems with channels ranging in diameter from 25 to 200 µm, one bifurcation 
or multiple bifurcations, and channel expansions and contractions were fabricated for these 
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studies. Relative flow resistances were calculated using the Poiseuille equation (Equation 8) to 
ensure that each branch will get sufficient flow.  
L
PrQ ⋅⋅
∆⋅⋅= µ
π
8
4
                                                                                                       (8) 
The channel design was drawn using a computer-aided design program (Adobe Illustrator) and 
was initially printed on a transparency using a high-resolution commercial printer to create a 
photolithographic mask. Preliminary fabrication using a transparency mask produced channels 
with rather rough edges. Therefore, in order to obtain channels with smooth, straight walls 
necessary for clear visualization of a developed near wall plasma layer, a chrome mask 
(fabricated at Penn State University), which significantly improved the resolution, was used. A 
resolution of ~ 500 nm can be obtained using a chrome mask compared to > 20 µm with a 
transparency mask [83]. Sample microchannel system designs are shown in Figure 4-1.   
A negative photoresist, SU-8 2050 (Microchem), was spin-coated on either a three or 
four inch silicon wafer at a spin speed of 3000 rpm in order to control the channel height close to 
100 µm. The resist was then soft baked in order to evaporate solvent and increase film density. 
The mask and wafer were exposed to near ultra-violet light, which produced the pattern of the 
mask in the photoresist. After exposure, the wafer was baked and submerged in a developer in 
order to remove unexposed photoresist. Since SU-8 is a negative resist, exposed areas were 
cross-linked and remained on the wafer after development. Following development, the 
patterned wafer was hard baked to remove remaining solvent from the photoresist.   
A replica molding technique was then used to create a negative replica of the master in 
polydimethyl siloxane (PDMS). PDMS was an excellent choice for this application since it is 
strong, inexpensive, transparent, non-toxic, and can effectively reproduce features on the micron 
scale using replica molding [83]. The PDMS was poured over the mold, placed under vacuum to 
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remove air bubbles, cured in an oven at 60ºC for four hours, and then peeled from the master. 
This step provided three of the four walls of the channels. Access holes were then punched using 
a blunt needle, and the PDMS replica was sealed to a flat glass surface (cover glass) using an 
irreversible sealing technique where both surfaces were exposed to an air plasma, which 
introduced silanol groups on the surfaces, which in turn formed covalent bonds creating an 
irreversible seal [83]. Finally, the channels were placed in an oven at 60ºC overnight in order to 
strengthen the bond between the glass and PDMS 
. 
     
Figure 4-1. Sample microchannel design (left) and the chrome mask used for microchannel 
fabrication (right) 
 
 Cross sections of unsealed PDMS channels and of photoresist designs on the silicon 
wafer were cut, and light microscopy (PDMS channels) and scanning electron microscopy 
(silicon wafer) were used to verify the shape and dimensions of the channels. Figure 4-2 shows a 
cross section of a 100 µm segment of a PDMS channel (top left), an intact channel contraction 
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from 200 µm to 100 µm (top right), and scanning electron micrographs of cross sections of 200 
µm and 50 µm segments of the photoresist on the silicon wafer (bottom left and right, 
respectively). All channel heights were verified to be ~ 100 µm.     
  
 
Figure 4-2.  Micrographs of PDMS microchannels and the silicon wafer/photoresist master 
4.1.2 Preparation of a red blood cell (RBC) suspension 
Bovine blood was obtained from a local slaughterhouse. Bovine blood was chosen since it is 
easier to obtain and work with and less expensive than human blood and is often used in in vitro 
modeling of physiological and pathophysiological effects in the cardiovascular system [54, 87-
89]. The RBCs were washed three times with phosphate buffered saline (PBS) and resuspended 
at a hematocrit of either 20% or 40% in PBS with 1% bovine serum albumin added to preserve 
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the biconcave shape of the cells. A hematocrit of 20% was chosen for the majority of the studies 
in capillary tubes and microchannels since in vivo microcirculatory hematocrit ranges between 
20 and 50% of systemic hematocrit [56, 84] due to the Fåhraeus Effect which is more 
pronounced at lower hematocrit for a given vessel diameter [56]. A hematocrit of 40% also was 
used for several studies in order to mimic physiological hematocrit in the larger vessels since 
studies were performed in capillary tubes with a wide range of diameters. DRP (saline in 
controls) was added to the suspension at various concentrations and incubated at room 
temperature for at least one hour. Light microscopy was used to verify normal biconcave shape 
of the RBCs. 
 All in vitro blood flow experiments were performed at room temperature. Previous 
experiments, where blood viscosity with and without polymer was measured in a rotational 
viscometer at both room temperature and 37°C, showed that the addition of polymer did not 
change the temperature dependence of blood viscosity. Therefore, it was appropriate to perform 
the experiments at room temperature. 
4.1.3 Effects of DRPs on blood flow in straight capillary tubes 
The effects of DRPs on the flow of RBCs in a straight channel in laminar flow were studied 
using a flow system (Figure 4-3) consisting of a syringe pump (Harvard Apparatus), a pressure 
transducer (PCB Piezotronics), and a capillary tube with a known diameter ranging from 115-
1300 µm in order to test the hypothesis that DRPs attenuate the Fåhraeus-Lindquist Effect. 
Experiments were performed using tubes with a wide range of diameters and lengths in order to 
determine how the DRPs’ influence on blood flow is affected by capillary tube dimensions. In 
order to prevent RBC sedimentation, the suspension in the syringe was kept well mixed by 
 55 
placing a small magnetic stir bar inside the syringe, and manually agitating it using another 
magnet on the outside. Length of collective tubing was minimized to avoid cell settling in the 
tubing as much as possible.   
 
Capillary tube
Pressure 
transducer
Flow
Syringe pump with flow control  
Figure 4-3. Schematic of capillary flow system. 
 
Flow rates varied from 0.05 to 20 ml/min in order to match physiological shear rates and 
Reynolds numbers. Reynolds number was calculated using Equation 3, and wall shear stress (τw) 
was calculated using 
L
dP
w *4
*∆=τ                                                                                                      (9) 
where ∆P is the pressure drop across the tube, d is tube diameter, and L is tube length. Reynolds 
number and calculated wall shear stress values for the tubes used in this study are shown in 
Table 4-1. In vivo, small arteries and arterioles have diameters ranging from 0.02 to 0.1 cm, flow 
rates ranging from 0.004 to 5 ml/min, and Reynolds numbers ranging from 0.4 to100 [85]. 
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Table 4-1. Reynolds number and calculated wall shear stress for blood flow in capillary tubes 
Diameter Reynolds Wall Shear 
µm Number Stress (N/m2) 
115 1-20 10-70 
220 5-30 3-20 
410 10-260 2-50 
560 30-380 5-40 
860 20-250 1-11 
1300 10-170 0.3-3 
 
RBC suspensions with a hematocrit of 20% were used for all studies. For the experiments 
run in the 115 µm tube, a suspension with a hematocrit of 40% was tested as well. DRP 
concentrations of 2, 10, 20, and 100 µg/ml were applied in this study. A concentration of 2 µg/ml 
represents an effective concentration for in vivo use, while slightly higher concentrations led to a 
stronger effect and therefore easier quantification of the DRP effect on microscale blood flow. 
Pressure vs. flow relationship was determined for each polymer concentration and compared to 
the control RBC suspension. Friction factor was calculated using Equation 4 as described in 
3.1.1 and compared to a theoretical friction factor for laminar flow calculated by Equation 10,  
            
Re
64=λ                                                                                                   (10)  
which can be derived by substituting the Poiseuille equation into the Darcy-Weisbach equation. 
An increase in pressure gradient, and therefore friction factor, indicated attenuation of the 
Fåhraeus-Lindquist Effect. Mean friction factors were compared using one-way ANOVA and 
unpaired, two-sample Student’s t-tests assuming unequal variances with two-tail distribution. 
Data are presented as mean ± standard deviation.   
While physiological blood flow is pulsatile, steady flow was chosen for the current 
studies since it is much easier to quantify and model, and since pulsatility is significantly 
diminished in microvessels [59, 86]. Although real blood vessels are distensible, the current 
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microflow studies were performed in tubes with rigid walls in order to be able to quantify DRP 
effects on the wall shear stresses via measurements of pressure gradients across a microchannel. 
If an increase in pressure gradient is seen after the addition of DRP to blood, it can be assumed 
that in an in vivo situation this would cause vasodilation. However, to quantitatively characterize 
the changes in the microchannel flow produced by DRP additives, application of channels with 
rigid walls is valuable. Pressure versus flow relationships were determined for both control and 
DRP suspensions in the same tubes at the same flow rates in order to ensure that there is no 
difference in surface roughness between tests.  
Entrance length (le), defined as the length needed for the velocity profile to become fully 
developed, was calculated [74] using  
       ,                                                                                           (11)   dle ⋅⋅= Re06.0
where d is tube diameter. Tubes were selected to be sufficiently long, and therefore the 
assumption of fully developed, steady, laminar flow is valid.   
Entrance and exit effects were also considered. It was shown that drag reducing ability 
correlates well with elongational viscosity [87], and, since the flow at the entrance to a tube is 
highly elongational, the effects of this elongational viscosity on the pressure versus flow 
relationship in the tube must be determined. These effects were examined through capillary 
blood flow experiments in tubes of the same diameter with different lengths. Since the flow is 
laminar, the pressure drop per unit length along the tube should be constant for a constant flow 
rate. If this is not the case in the tubes of different length, the difference can be attributed to 
entrance effects. Mean pressure drop per unit length was calculated for a 220 µm diameter tube 
with a length of 50 mm and one with the same diameter but a length of 100 mm and compared 
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using an unpaired, two-sample Student’s t-test assuming unequal variances with two-tail 
distribution. Exit effects can be assumed to be negligible since tubes exited to the atmosphere. 
4.1.4 Effects of DRPs on blood flow in bifurcated microchannels 
The effect of DRPs on the flow of RBCs in microchannels was studied using the PDMS channels 
fabricated in 4.4.1. Bovine RBC suspensions were prepared using the method outlined in 4.1.2. It 
was previously shown that feed hematocrit, diameter, and flow rate distribution between 
branches are the most important factors in determining RBC distribution at a bifurcation [57], 
and therefore these parameters were carefully considered in experimental design. Cell 
distensibility, suspension medium, flow rate in the parent branch, and bifurcation geometry, on 
the other hand, were shown to have little or no influence on RBC distribution at the bifurcation 
[57]. In channels with parent branch diameters greater than 50 µm, it was also shown that ratio of 
parent channel diameter to daughter channel did not affect RBC distribution between the 
branches [88]. All experiments in this study were performed with parent channels having 
diameters of 50 µm or greater. A syringe pump (Harvard Apparatus) in infuse mode was used to 
generate flow of the RBC suspensions through the channels fabricated in 4.1.1. Flow rates 
ranging in the parent channel from 0.01 to 0.2 ml/min, depending on channel dimensions, were 
used for these experiments. Reynolds numbers ranged from 1 – 20. A schematic of the 
microchannel flow system is shown in Figure 4-4.  
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Figure 4-4. Schematic of microchannel flow system 
 
In a separate set of experiments blood samples were collected from each outlet, and 
hematocrits were measured using a standard microcapillary technique. These experiments were 
performed in bifurcated channels with a parent branch diameter of 50 µm and a daughter branch 
diameter of 25 µm since the Fåhraeus, Fåhraeus-Lindquist, and plasma skimming effects become 
more pronounced as tube diameter is decreased. Depth of both channels was 100 µm. A flow rate 
of 0.1 ml/min was used for this experiment giving Re ~ 15 in the channel upstream of the 
bifurcation. It was estimated that almost 90% of the flow went through the parent channel. Wall 
shear stress was calculated to be ~ 250 N/m2. Blood samples were collected directly into 
microcapillary tubes in order to minimize sedimentation in connective tubing. The outlet 
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hematocrit values from the parent and daughter branches were compared to each other using an 
unpaired, two-sample Student’s t-test assuming unequal variances with two-tail distribution. 
These values were compared in both the DRP and control samples in order to directly determine 
whether the DRPs were attenuating the plasma skimming effect. Data are presented as mean 
hematocrit ± standard deviation.  
As the RBCs flowed through the microchannels under physiologically relevant pressures 
and flow rates ranging from 0.01 to 0.2 ml/min, their flow behavior was recorded with a 
microscopic flow imaging system (Figure 4-5), which consists of an inverted research 
microscope (IX70, Olympus, NJ), a cooled CCD camera (MicroMax DIF, Roper Scientific, NJ), 
and an associated image acquisition board hosted in a PC. The illuminated flow field was imaged 
and recorded by the CCD camera. At least twenty images were recorded at each condition. The 
control RBC suspension with no polymer added was run first in order to adjust the depth of focus 
to visualize a clear near-wall plasma layer. The suspension was then replaced with RBC samples 
containing DRP without moving the channel or changing the focus. Finally, the control 
suspension was tested again to ensure that the plasma layer was still visible. Image J (a version 
of NIH image software) was used to quantify the size of the cell free plasma layer in each image. 
In each image, the cell free area along a given length of the channel was identified manually and 
quantified using the Analyze Particle tool. Mean plasma layer size was compared between the 
control and DRP case using an unpaired, two-sample Student’s t-test assuming unequal variances 
with two-tail distribution. At least five images were analyzed in each case. Results are presented 
as mean plasma layer size ± standard deviation. Areas in the main channel and the smaller 
branch, as well as the bifurcation itself and channel expansions/contractions were imaged.  
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Images were also taken in a straight glass microchannel having a diameter of 100 µm 
since its dimensions were well defined, and the plasma layer could be easily observed and 
quantified. Reynolds numbers in this channel ranged from 1 – 20 and shear stress ranged from 5 
– 70 N/m2. At least five images were analyzed in each case. Results are presented as mean 
plasma layer size ± standard deviation.  
 
Figure 4-5. System for microflow experiments consisting of: a) syringe pump, b) syringe, c) PVC 
tubing, d) microchannel, e) reservoir, and f) inverted microscope 
4.1.5 Model for DRP effects on microcirculation 
Using the marginal zone model developed by Haynes [89], blood flow in small capillary 
tubes (diameter < ~ 500 µm) can be described and size of the near wall plasma layer can be 
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predicted with and without DRP additives. Blood flow was modeled as steady flow of a two-
phase fluid through a cylindrical tube with a core region of RBCs and a cell free plasma region 
near the wall. A schematic is shown in Figure 4-6  
 
Figure 4-6. Schematic used for marginal zone model of capillary blood flow 
 
Newtonian behavior was assumed in each region. Therefore, in the core RBC region  
L
rPP
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dv L
RBC
z
RBCrz ⋅
⋅−=−=
2
)( 0µτ                                        (12)                                        
where τrz is the shear stress, µRBC is the viscosity of the RBC region, vzRBC is the axial component 
of the velocity, (P0-PL) is the pressure drop over the tube, r is the tube radius, and L is the tube 
length. µRBC was assumed to be equal to bulk viscosity of the blood measured using a rotational 
rheometer. Boundary conditions can be written such that  
 0=
dr
dv RBCz  at r = 0 since axial velocity is at a maximum at the centerline of the tube and 
przRBCrz
ττ =  at r = R - δ, where δ is the size of the plasma layer, since the transport of 
momentum must be constant across the interface between the RBC and plasma layer. For the 
plasma region                          
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where µp is the plasma viscosity and vzp is the axial component of the velocity. In this case, 
experimental data were collected using RBCs suspended in PBS, and, therefore, µp is equal to 
the viscosity of water. Boundary conditions can be written as 
p
z
RBC
z vv =  at r = R - δ since the velocity in each region must be the same at the interface 
and 
p
zv  = 0 at r = R because of the no slip boundary at the tube wall. Integration of Equations 
11 and 12 gives the axial velocity profile in each region given in Equations 14 and 15. 
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Flow rates (Q) for each region can then be obtained using Equations 16-19. 
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The sum of the two fractions QRBC and Qp gives the total flow rate in the tube, Q. 
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Using the Poiseuille equation, Q = )( 0 LPP −  π r 4 / 8 µ L, and Equation 20, the apparent viscosity 
in the tube can be calculated as 
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Using these equations and the experimental data obtained from capillary and 
microchannel blood flow experiments, the effects of DRPs on the size of the near wall plasma 
layer in tubes of different diameter can be calculated.  
4.2 RESULTS 
4.2.1 Effects of DRPs on blood flow in straight capillary tubes  
Preliminary studies of the effects of DRPs on blood flow in straight capillary tubes were 
conducted using tubes ranging in diameter from 0.41 to 1.3 mm. All data were normalized for 
solution viscosity calculated using the Poiseuille equation and data obtained by running 
suspension media with no RBCs through the flow system. Table 4-2 shows specifications for the 
tubes tested and the increase in wall shear stress observed in each case. In the larger tubes, where 
the Fåhraeus-Lindquist Effect did not occur (0.86 and 1.3 mm), the DRPs had no effect on the 
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wall shear stress. In the smaller tubes (0.41 and 0.56 mm), the DRPs produced a significant 
increase in wall shear stress due to the attenuation of this effect.   
 
Table 4-2. Tube specifications and increase in wall shear stress caused by DRPs in blood flow in a 
straight channel 
Diameter Length 
Flow 
Rates 
Reynolds 
Numbers 
Shear 
Rates Increase in wall shear stress (%) 
(mm) (cm) (ml/min)  (1/s) 
No 
DRP 
10 µg/ml 
PEO-
4500 
20 µg/ml 
PEO-
4500 
20 µg/ml 
AVP 
100 µg/ml 
PEO-4500 
0.41 3.5 0.5-10 10-260 
1200-
67000 0 42 40 18 N/A 
0.41 12.7 0.5-2 10-60 
1200-
9000 0 N/A 23 15 22 
0.56 7.5 2-20 30-380 
1400-
20000 0 15 N/A N/A N/A 
0.86 13 2-20 20-250 
400-
5500 0 2 N/A N/A N/A 
1.3 61.5 2-20 10-170 
100-
1600 0 0 0 0 N/A 
 
Based on the results of these preliminary studies, which confirmed that the Fåhraeus-
Lindquist Effect was more pronounced in smaller tubes, additional studies were performed in 
capillary tubes with diameters of 220 µm and 115 µm. In the 220 µm capillary with length of 50 
mm, 10 µg/ml PEO-4500 caused an average increase in wall shear stress of 11%, and 20 µg/ml 
PEO-4500 caused an increase of 14% (p < 0.01 at all but the lowest flow rate). In the 220 µm 
capillary with length of 100 mm, PEO-4500 increased wall shear stress by 9% and 26% at 
concentrations of 10 and 20 µg/ml respectively (p < 0.05 at all flow rates and p < 0.01 at all but 
the lowest flow rate). Figure 4-7 shows friction factor vs. Reynolds number for blood flow in the 
tube with length of 100 mm. In the control case, the experimental friction factor was 
significantly lower than the theoretical due to lower near wall viscosity. When DRP was added, 
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however, the friction factor was significantly increased. Similar results were seen in the tube 
with length of 50 mm.  
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Figure 4-7. Friction factor vs. Re for RBCs flowing in a 220 µm capillary tube 
 
An even more significant effect was seen in the 115 µm capillary tube where the addition 
of 10 µg/ml PEO-4500 caused an increase in wall shear stress of 24% at a hematocrit of 20% and 
52% at a hematocrit of 40%. Figures 4-8 and 4-9 show friction factor vs. Reynolds number for 
flow of RBCs in this tube at hematocrits of 20% and 40% respectively. In the control case, the 
experimental friction factor is significantly lower than the theoretical. The experimental friction 
factor increased with the addition of 10 µg/ml DRP, likely due to RBCs relocating to the near 
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wall space. Similar effects were observed with the addition of other DRPs including PAM, HA, 
and AVP. 
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Figure 4-8. Friction factor vs. Re for RBCs (Ht = 20%) with 0 and 10 µg/ml PEO-4500 flowing in a 
115 µm capillary tube 
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Figure 4-9. Friction factor vs. Re for RBCs (Ht = 40%) with 0 and 10 µg/ml PEO-4500 flowing in a 
115 µm capillary tube 
 
The effects of PEO-4500 at a concentration of 2 µg/ml in 115 µm capillary tube were 
also investigated since this concentration was found to be effective at improving hemodynamics 
in vivo. The addition of PEO caused an increase in wall shear stress of 8% at a hematocrit of 
20% and 26% at a hematocrit of 40%. Figures 4-10 and 4-11 show friction factor vs. Reynolds 
number for flow of RBCs in this tube at hematocrits of 20% and 40% respectively. In the control 
case, the experimental friction factor is significantly lower than the theoretical. Although the 
effect was not as strong as in the 10 µg/ml case, the experimental friction factor significantly 
increased with the addition of 2 µg/ml DRP compared to control. This increase in friction factor 
was clearly due to reduction of near wall plasma layer size and increase in the near-wall 
viscosity.  
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ANOVA showed that the addition of DRPs had a significant effect on wall shear stress 
when RBCs flowed through the 115 µm tube at all flow rates (p < 0.05 in all cases and p << 
0.001 for all flow rates at 40% Ht and all flow rates except 0.05 ml/min at 20% Ht). A Student’s 
t-test showed that the addition of 10 µg/ml PEO to flowing RBCs produced a statistically 
significant increase in wall shear stress at all tested flow rates and hematocrits (p<0.01). The 
addition of 2 µg/ml PEO produced a statistically significant increase in wall shear stress at all 
tested flow rates at a hematocrit of 40% (p<0.01) and the all but the lowest flow rate at 20% Ht 
(p<0.05). 
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Figure 4-10. Friction factor vs. Re for RBCs (Ht = 20%) with 0 and 2 µg/ml PEO-4500 flowing in a 
115 µm capillary tube 
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Figure 4-11. Friction factor vs. Re for RBCs (Ht = 40%) with 0 and 2 µg/ml PEO-4500 flowing in a 
115 µm capillary tube 
 
Additionally, in the 220 µm capillary tube, pressure drop per unit length was calculated 
in the tubes of different lengths (50 and 100 mm). No significant difference was seen between 
these values for the different length tubes (p > 0.01 in all cases). Therefore, it can be concluded 
that entrance effects were negligible for these studies.   
4.2.2 Effects of DRPs on blood flow in straight glass microchannels 
The effect of DRPs on the near wall plasma layer was investigated in a straight glass 
microchannel with a square cross section measuring 100 µm x 100 µm and a length of 2.5 cm 
(Figure 4-12). A developed near wall cell free plasma layer can be seen in the control suspension 
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of 20% Ht RBCs flowing at 0.2 ml/min. When a DRP, PEO-4500 in this case, was added to the 
suspension at a concentration of 10 µg/ml, the RBCs were shifted closer to the channel wall, 
significantly reducing the size of the plasma layer and became elongated. The RBC elongation 
likely occurred due to the increased stress on the RBCs caused by their proximity to the channel 
walls. However, there is also a possibility that the RBC elongation might be caused in part by 
some direct effect of the DRPs on the RBC membrane. When flow was stopped, there was a 
slight but statistically significant difference between plasma layer size in the control suspension 
(1.68 µm) and that with PEO (1.12 µm, p<0.001). The presence of a plasma layer, especially in 
the control case, is likely due to the fact that, although the pump was stopped, some flow still 
existed in the channel (a delay with imaging after stop of the pump would allow RBCs to settle). 
During flow, the plasma layer increase was significantly larger in the control suspension than in 
the PEO suspension (p<0.001 at 0.05 ml/min and at 0.1 ml/min). In the control suspension, the 
plasma layer sized increased from 1.68 µm to 5.5 µm when flow was increased from 0 to 0.1 
ml/min. When 10 µg/ml PEO was added to the suspension, however, an increase in flow rate 
from 0 to 0.1 ml/min only caused the plasma layer to increase from 1.12 to 1.3 µm. Figure 4-13 
shows the increase in plasma layer size with increase in flow rate for the control suspension, and 
the significant decrease in near wall plasma layer size caused by DRP addition. Data are 
presented as the average plasma layer size of five frames ± standard deviation. Similar results are 
seen with other DRPs including PAM, AVP, and HA. However, polymers that have no drag 
reducing ability, such as PEO-200 and high molecular weight dextran, produced no effect on the 
cell-free layer.   
Pressure gradient was also measured over the 100 µm x 100 µm x 2.5 cm straight glass 
microchannel. In the control case, experimental pressure was found to be lower than theoretical. 
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The addition of a DRP, 10 µg/ml PEO-4500, led to an increase in pressure gradient, and thus in 
wall shear stress, compared to control RBCs at all but the lowest tested flow rate. Pressure 
increases were statistically significant (p < 0.01) at the higher flow rates. Figure 4-14 shows the 
friction factor vs. Re in the rectangular glass microchannel for both control RBCs and RBCs with 
10 µg/ml PEO. These results confirm that the DRPs cause a similar phenomenon in rectangular 
channels to that observed in tubes with a circular cross section. This validates the use of 
bifurcated microchannels with rectangular cross sections to investigate the effects of DRPs on 
RBC behavior at bifurcations. 
 
 
 
 73 
 Figure 4-12. RBCs in a 100 µm straight, glass channel with no polymer and no flow (top left) and 
flowing at 0.2 ml/min (top right) and with 10 µg/ml PEO-4500 and no flow (bottom left) and flowing at 0.2 
ml/min (bottom right) 
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Figure 4-13. DRP (PEO-4500) caused a significant decrease in plasma layer size in a 100µm glass 
channel (p<0.001 at 0.05 ml/min and 0.1 ml/min) 
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Figure 4-14.  Friction factor vs. Re for RBCs (Ht = 20%) with 0 and 10 µg/ml PEO-4500 flowing in a 
100 µm rectangular microchannel 
4.2.3 Effects of DRPs on blood flow in bifurcated microchannels  
The effect of DRPs on the flow of RBCs in PDMS microchannel systems was then studied in 
order to determine the potential effects that DRPs have on blood flow at bifurcations in the 
vascular system in vivo. Images were first taken upstream of the bifurcations, in the straight 
section of the PDMS microchannel to confirm that RBCs behaved the same in PDMS as in glass, 
and to ensure that a near wall plasma layer did form in the fabricated channels. Images such as 
those in Figure 4-15 verified that the PDMS channels could be used to visualize the near wall 
plasma layer. As in the glass channels, when PEO-4500 was added at a concentration of 10 
µg/ml to the suspension of flowing RBCs (20% Ht) in the PDMS channel, the RBCs became 
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more elongated and moved closer to the channel wall, causing a reduction in size of the plasma 
layer. When flow was stopped, no significant difference in plasma layer size between the control 
and PEO (p=0.76) was seen. However, during flow, the plasma layer was significantly larger in 
the control suspension than in the suspension containing PEO (p=0.01 at 0.05 ml/min and 
p<0.001 at 0.1 ml/min). Figure 4-16 shows the increase in plasma layer size with increase in 
flow rate for the control suspension, and the decrease in near wall plasma layer size when DRP 
was added. Data are presented as the average plasma layer size calculated from frames ± 
standard deviation. Similar results were seen with the addition of other DRPs such as PAM, 
AVP, and HA.   
 
Figure 4-15. RBCs in a 100 µm PDMS channel upstream of the bifurcations with no polymer and no 
flow (top left) and flowing at 0.1 ml/min (top middle) and 0.2 ml/min (top right) and with 0.01 mg/ml PEO-
4500 and no flow (bottom left) and flowing at 0.1 ml/min (bottom middle) and 0.2 ml/min (bottom right) 
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Figure 4-16. DRP (PEO-4500) caused a significant decrease in plasma layer size in a 100 µm section 
of a PDMS channel upstream of bifurcations (p=0.01 @ 0.05 ml/min and p<0.001 @ 0.1 ml/min) 
 
Next, the DRP effects on RBC distribution at microchannel bifurcations were directly 
visualized using the methods described in 2.1.4. Figure 4-17 shows the locations in the channels 
where images were taken. Images were taken in both 100 µm to 100 µm (Figure 4-18) and 100 
µm to 50 µm (Figure 4-19) bifurcations with bifurcation angles of 90º. In both cases, a 
developed near wall plasma layer can be seen as control RBCs flow through the bifurcations. 
Flow direction in each image is indicated by the arrows. When DRPs, either PEO-4500 or AVP, 
were added at a concentration of 10 µm/ml, the RBCs were relocated to this near wall region, 
greatly reducing the plasma layer size. Due to the decrease in the size of the near wall plasma 
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layer with the addition of DRPs, more RBCs would flow into the daughter branch, lessening the 
plasma skimming effect. When flow was stopped, no difference in plasma layer size was 
observed between RBCs with and without DRP.  
 
 
Figure 4-17.  Schematic of microchannel systems highlighting regions where images were taken in 
100 µm to 100 µm bifurcation (left) and 100 µm to 50 µm bifurcation (right). Arrows indicate direction of 
flow. 
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 Figure 4-18. RBC suspensions in a 100 µm to 100 µm right angle bifurcation with no polymer and no 
flow (top left) and flowing at 0.1 ml/min (top middle) and 0.2 ml/min (top right) and with 10 µg/ml PEO-4500 
and AVP and no flow (middle and bottom left, respectively) and flowing at 0.1 ml/min (middle and bottom 
middle) and 0.2 ml/min (middle and bottom right) 
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 Figure 4-19. RBC suspensions in a 100 µm to 50 µm right angle bifurcation with no polymer and no 
flow (top left) and flowing at 0.1 ml/min (top middle) and 0.2 ml/min (top right) and with 10 µg/ml PEO-4500 
and no flow (bottom left) and flowing at 0.1 ml/min (bottom middle) and 0.2 ml/min (bottom right) 
 
Finally, in a 50 µm to 25 µm bifurcation, blood samples were collected from the outlets 
of both the parent and daughter branch as well as from the feed syringe. Hematocrit was 
measured for each sample. In the control case, the parent hematocrit was found to be 
significantly higher than that in the daughter branch (p < 0.001), showing that plasma skimming 
was occurring in this system. Parent branch hematocrit was 19.0% ± 1.1%, while the daughter 
branch hematocrit was 17.1% ± 1%. When 10 µg/ml PEO-4500 was added, however, the plasma 
skimming effect was attenuated, and no significant difference was observed between parent and 
daughter branch hematocrit (p = 0.6). Hematocrit in the parent channel and daughter channel 
were 18.3% ± 1.3% and 18.6% ± 2.2% respectively. Feed hematocrit was 18.6% ± 1.3%, and no 
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significant difference between feed hematocrit in the control and polymer RBC suspensions was 
observed (p > 0.1). Figures 4-20 and 4-21 compare hematocrits measured from blood samples 
taken from the inlet and each outlet of the channel both in the control case and with the addition 
of DRP. 
 
Control 
15
17
19
21
H
em
at
oc
ri
t (
%
)
Parent Branch Daughter Branch Feed
 
Figure 4-20.  Comparison of hematocrits at the channel inlet and outlets of the parent and daughter 
branch. For RBC suspensions with no DRP flowing at 0.1 ml/min in a 50 µm to 25 µm bifurcation, parent 
branch hematocrit is significantly higher than that in the daughter branch indicating that plasma skimming 
is occurring 
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Figure 4-21. Comparison of hematocrits at the channel inlet and outlets of the parent and daughter 
branch. For RBC suspensions with 10 µg/ml PEO-4500 flowing at 0.1 ml/min in a 50 µm to 25 µm bifurcation, 
the plasma skimming effect is attenuated and no significant difference is observed between parent and 
daughter hematocrit. 
   
An interesting effect was observed when DRPs were added to RBCs (20% Ht) flowing 
through a channel expansion. The addition of 10 µg/ml PEO-4500 to RBCs flowing through the 
expansion caused a redistribution of RBCs at flow separations. As shown in Figure 4-22, at a 
channel expansion from 50 µm to 200 µm with flow from top to bottom, significant flow 
separation and formation of pockets of plasma can be seen in the control blood at the expansion. 
When DRP was added, however, the RBCs were relocated to the near wall region eliminating the 
plasma pockets at the expansion, and the flow separation was reduced. This effect became more 
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apparent as flow rate was increased, and no difference was seen between the control and DRP 
case when flow was stopped. A similar effect was observed in a 100 µm to 200 µm expansion, 
both with 20% hematocrit (Figure 4-23) and 40% hematocrit (Figure 4-24) RBCs, although the 
recirculation zone was much smaller in the 40% Ht case. 
 
Figure 4-22. 20% hematocrit RBC suspension in a 50 µm to 200 µm expansion with no polymer and 
no flow (top left) and flowing at 0.1 ml/min (top middle) and 0.2 ml/min (top right) and with 10 µg/ml PEO-
4500 and AVP and no flow (middle and bottom left, respectively) and flowing at 0.1 ml/min (middle and 
bottom middle) and 0.2 ml/min (middle and bottom right) 
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Figure 4-23. 20% hematocrit RBC suspension in a 100 µm to 200 µm expansion with no polymer and 
no flow (top left) and flowing at 0.1 ml/min (top middle) and 0.2 ml/min (top right) and with 10 µg/ml PEO-
4500 (bottom left) and flowing at 0.1 ml/min (bottom middle) and 0.2 ml/min (bottom right) 
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 Figure 4-24. 40% hematocrit RBC suspensions in a 100 µm to 200 µm expansion with no polymer 
and no flow (top left) and flowing at 0.1 ml/min (top middle) and 0.2 ml/min (top right) and with 10 µg/ml 
PEO-4500 (bottom left) and flowing at 0.1 ml/min (bottom middle) and 0.2 ml/min (bottom right) 
4.2.4 Model for DRP effects on microcirculation 
Based on in vitro and in vivo experiments, in vessels with diameters greater than 100 µm at a 
hematocrit of ~ 40 % and flow rates high enough to prevent aggregation, the size of the near wall 
plasma layer is likely to be no larger than 4 µm [56]. This agrees well with the plasma layer sizes 
calculated using Equation 21, derived from the marginal zone theory, for the studies of flow of 
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RBCs through the 115 µm capillary tube which range from 1 to 4 µm depending on flow rate and 
hematocrit. When DRP was added to the RBCs, plasma layer size calculated using this model 
was reduced. When 10 µg/ml PEO-4500 was added to RBCs flowing in the 115 µm capillary 
tube, plasma layer size was calculated to be between -2 and 1 µm depending on flow rate and 
hematocrit. The negative plasma layer size, while physically impossible, may indicate that RBCs 
are actually more concentrated in the near wall region than in bulk flow. This is qualitatively 
supported by the imaging studies described in 4.2.1, where the RBCs appear to be more 
concentrated in the near wall region than in the bulk flow when DRP is added to the RBC 
suspension. Using the same method for RBCs flowing in the 100 µm microchannel, plasma layer 
size was calculated to be 3.4 µm for control RBCs flowing at 0.05 ml/min and 4.4 µm at 0.1 
ml/min. When 10 µg/ml PEO-4500, calculated plasma layer size was reduced to 2.0 µm and 0.6 
µm at 0.05 and 0.1 ml/min respectively. These results agree relatively well with the measured 
plasma layer size (4.3 µm for control RBCs flowing at 0.05 ml/min and 5.5 µm at 0.1 ml/min and 
1.4 µm at 0.05 ml/min and 1.3 µm and 0.1 ml/min with 10 µg/ml PEO-4500). 
4.2.5 Results Summary 
Overall, the following major results were obtained through the studies performed in this 
specific aim. 
• The addition of DRPs to a RBC suspension flowing in a microchannel produced a 
significant increase in wall shear stress. 
• A significant decrease in near wall plasma layer size was observed when DRPs 
were added to a RBC suspension flowing in a microchannel. 
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• When DRP was added to a RBC suspension flowing through a channel expansion, 
RBCs were relocated to the near wall region, eliminating the plasma pockets at 
the expansion and reducing flow separation in this area. 
• DRPs significantly decreased the plasma skimming effect at a channel bifurcation 
increasing the hematocrit of the blood flowing through the daughter branch. 
4.3 DISCUSSION 
At the present time, neither the Fåhraeus and Fåhraeus-Lindquist (F-L) Effects nor the drag 
reducing polymer phenomenon is fully understood. Although the drag reducing phenomenon is 
completely different from the Fåhraeus and F-L effects, the studies performed in this specific 
aim indicate that these phenomena may unite in the vascular system to produce interesting 
consequences which can potentially be beneficial in both microfluidic technology and medicine. 
The observed redistribution of RBCs across the microchannels and reduction of plasma 
layer size caused by DRPs are intriguing scientific phenomena. The prevention of RBC 
movement toward the center of the vessel by DRPs may improve the transport function of blood 
in the microcirculation and facilitate gas transport between RBCs and tissue in vivo by reducing 
diffusion distance. This effect could also potentially be extremely beneficial in facilitating gas 
exchange and reducing thrombosis (by reducing recirculation zones) in blood contacting 
artificial organs and bioreactors. The observed increases in the near-wall hematocrit and in local 
viscosity with the addition of DRPs produce an increase in wall shear stress in the 
microchannels. In microvessels, this increase in wall shear stress would cause release of 
endothelial-derived relaxing factor composed of nitric oxide [59], promoting vasodilatation and 
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thus decreasing overall vascular resistance. In vivo experiments have shown that DRPs cause a 
decrease in vascular resistance [12, 16, 38, 39], and local vasodilation caused by RBC 
redistribution could be one of the mechanisms responsible for this effect. The observed increase 
in wall shear stress caused by DRPs could also lead to an increase in number of functioning 
capillaries, which has been seen with the injection of DRPs in previous in vivo studies [3]. In the 
case of hemorrhagic shock, the reduction in plasma skimming at vessel bifurcations might 
improve microcirculation, delivering more RBCs to the capillaries, and acting as an 
autotransfusion. This is extremely promising since it has been previously shown that adequate 
functional capillary density is a major factor of survival in hemorrhagic shock [42].  
 The reduction of flow separations and elimination of the “plasma pocket” region 
observed at channel expansions has potential clinical significance as well. It is known that 
thrombi are likely to form in areas of flow separation [90-92]. Studies by Karino and Goldsmith, 
performed with human platelets flowing in an expansion with a diameter ratio of 3.33 (151 µm to 
504 µm), suggested that the combination of long residence times, flow patterns, and fluid 
mechanical stresses present in vortices associated with flow separation lead to platelet 
aggregation and thus thrombus formation [91]. Moving RBCs closer to the wall would wash 
platelets out of this recirculating plasma zone and therefore could decrease thrombus formation. 
This would be beneficial not only in the vessels, but also in medical devices where thrombosis is 
one of the major concerns. Atherogenesis is known to occur in areas of flow separation where 
low flow and low shear stress conditions are present. The reduction in flow separation caused by 
DRPs and the movement of RBCs to the vessel wall and resulting increase in shear stress 
supports the results of previous studies which showed that DRPs can prevent and delay the 
development of atherosclerotic legions [2, 4, 9]. These findings suggest that DRPs produce a 
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novel phenomenon in blood flow in microvessels which could provide an exciting new avenue 
for the treatment of cardiovascular disorders.    
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5.0  DEVELOPMENT AND TESTING OF NEW DRAG REDUCING POLYMERS FOR 
POTENTIAL BIOMEDICAL APPLICATIONS 
Several DRPs, including high molecular weight PEOs, PAMs, and plant-derived polysaccharides 
were applied in previous in vivo studies and shown to have beneficial effects on blood 
circulation, but currently none is being clinically used . PAM was applied in many animal studies 
and shown to be very effective, but it is not ideal for use in vivo because of the known toxicity of 
the acrylamide monomer as well as certain biocompatibility issues [9, 93]. PEO was also shown 
to be effective in animal studies and is a good candidate for certain biomedical applications, but 
its rapid mechanical degradation, especially in the presence of RBCs, may present a major 
obstacle for use in treating chronic pathologies. Certain polysaccharides have also shown 
promise, but lack of consistency between preparations and of a method for production of large 
quantities are hurdles that must be overcome. Therefore, the search continues for new DRPs, 
which are biocompatible, mechanically stable, well defined, and easily manufactured, to be 
proposed for clinical uses. Three potential candidate DRPs have been identified that may meet 
criteria necessary for use in vivo. These include a natural DRP extracted from the aloe vera plant; 
poly(N-vinylformamide), a high molecular weight polymer synthesized from a non-toxic isomer 
of acrylamide; and hyaluronic acid, a high molecular weight polysaccharide known to have drag 
reducing properties and already approved by the FDA for some clinical uses (especially in the 
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veterinary practice) [73]. Each of these polymers was characterized and evaluated for its efficacy 
as a drag reducer and ability to withstand stress induced degradation. 
5.1 METHODS 
5.1.1 Development and characterization of an aloe vera based DRP 
Aloe vera DRP (AVP) was shown to be a very effective DRP, reducing resistance to 
turbulent flow in vitro by up to 50% at a concentration of 10 µg/ml, but is not well characterized 
or reproducible. It has long been known that plant components vary from plant to plant 
depending on plant age, part used, or where it was grown [94, 95]. A standard protocol for AVP 
preparation, which provides a relatively reproducible polymer, has been developed [34]. The 
AVP was extracted from freshly cut leaves of aloe vera plants obtained from Silverthorn Ranch 
Nursery (Fallbrook, CA). Leaves were removed from the aloe vera plant and sliced open 
lengthwise, and the exposed gel scraped from the interior of the leaves. The gel was then mixed 
with sterile saline. This mixture was filtered through several layers of cheesecloth and the 
resulting filtrate collected and stirred. The aloe vera extract was then centrifuged at 14,000 rpm 
for one hour at 4 °C. The resulting supernatant was collected and tested for drag reducing 
effectiveness in vitro using a circulating flow loop as described in 3.1.1. The DRP was then 
selectively precipitated from the supernatant using 100% ethanol. The precipitate was collected 
and dried overnight in a vacuum. The dried precipitate was then dissolved at a concentration of 
2.5 mg/ml in sterile saline with 0.1 mg/ml Gentamicin added as an antibacterial agent. Several 
days of slow stirring at 4 °C were required to dissolve the precipitate. When completely 
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dissolved, the polymer solution was again centrifuged and the supernatant was dialyzed against 
sterile saline using a Spectra/Por regenerated cellulose membrane (Spectrum Laboratories, Inc.) 
with a molecular weight cutoff of 50,000 Da. Dialysis removed any low molecular weight 
polymer or other low molecular weight impurities. 
The effect of lyophilization (freeze-drying) of the AVP on its efficacy upon reconstitution 
was investigated, since lyophilization of aloe might be beneficial for storage, transport, or 
sterilization. AVP solution was lyophilized using a Labconco Freezone 4.5 freeze dryer. 
Following lyophilization, the dry polymer was redissolved in normal saline.   
AVP was characterized using hydrodynamic and rheological methods as well as GPC as 
described in 3.1.1 – 3.1.5. Additional characterization was performed in an attempt to determine 
the chemical structure of the active, drag reducing component of AVP. Proteinase K and trypsin 
assays were used to rule out the presence of polypeptides in the active components of the 
preparation. Since trypsin and proteinase K are both serine proteases which digest proteins by 
hydrolyzing peptide bonds [96, 97], degradation of the polymer by these enzymes would indicate 
peptide bonds were present in the active DRP component of aloe. Then, an approach similar to 
that used in Chow et al [60], enzymatic digestion with endo-β-D-mannanse was used to make a 
preliminary determination of the residues and linkages in the backbone of AVP. After treatment 
with each enzyme, drag reduction tests of the AVP were used to determine enzymatic cleavage 
in the polymer backbone. A decrease in drag reducing ability, likely caused by a decrease in 
molecular weight, was used to indicate cleavage of the polymer.   
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5.1.2 Synthesis and characterization of poly(N-vinylformamide)  
An inverse emulsion polymerization technique described by Badesso et al. [68] was used to 
synthesize high molecular weight poly(N-vinylformamide) (PNVF). N-vinylformamide (NVF) 
monomer (Sigma-Aldrich) was distilled at 80°C under vacuum. The distilled NVF monomer (25 
ml), sorbitan monostearate (4.02 g), octane (145 ml), water (48 ml), and 2,2’-azobis(2,4-
dimethylpentanenitrile) (Vazo 52, 0.048 g, DuPont) reacted in a high-speed stirrer (500 rpm) at 
50°C for three hours under nitrogen. The reaction produced an emulsion, which was broken with 
excess acetone to yield high molecular weight PNVF. The PNVF was dried and then dissolved in 
distilled water at a concentration of 5 mg/ml. The PNVF solution was then dialyzed against 
distilled water using a Spectra/Por polyvinylidine difluoride membrane (Spectrum Laboratories, 
Inc.) with a 1x106 Da molecular weight cutoff to remove any unreacted monomer, low molecular 
weight polymer, and other impurities. The dialyzed PNVF was lyophilized and redissolved at a 
concentration of 5 mg/ml in distilled water or saline. Three lots of the polymer were synthesized. 
Each preparation was characterized using the hydrodynamic, rheological, and chemical methods 
described in 3.1.1 to 3.1.5. The preparation which was shown to have the best drag reducing 
properties was selected for the further studies, and results of these studies are presented in 5.2.2. 
1HNMR spectrum was recorded on a Bruker Avance 300 spectrometer, using deuterium oxide as 
a solvent. 1HNMR was used to confirm that the tested polymer was indeed PNVF and not the 
hydrolyzed form, poly(vinyl amine). 
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5.1.3 Characterization of hyaluronic acid (HA) as a DRP 
Several HA samples with various MWs were obtained from Lifecore Biomedical. The polymers 
were characterized, and their drag reducing efficacy and mechanical stability were investigated 
using the methods described in 3.1.1 – 3.1.5 in order to assess the potential of HA as a DRP for 
use in biomedical applications.   
5.1.4 Comparison and correlation of DRP physicochemical and rheological properties 
with their drag reducing activity and their effects on microchannel blood flow 
Correlations between physicochemical and rheological properties of the polymers and their drag 
reducing efficiency were evaluated. PEO-4500, AVP, PNVF, and HA, as well as PAM, were all 
included in the correlations. High molecular weight dextran was included as a negative control. 
Correlations with drag reducing ability were tested for molecular parameters including molecular 
weight, intrinsic viscosity, radius of gyration, and hydrodynamic radius, as well as viscoelastic 
properties of concentrated solutions including viscosity, elasticity, and relaxation time at low and 
high shear rates in order to show which properties correlated best with a polymer’s drag reducing 
efficiency. Correlations were also evaluated between these same molecular and rheological 
parameters and the DRP effects in microchannel blood flow studies. These correlations provided 
a better understanding of which properties best define and predict a polymer’s ability to improve 
microcirculation. 
Degradation behavior of the various DRPs in response to mechanical stresses was 
compared. This allowed for the prediction of the ability of the DRPs to withstand the mechanical 
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stresses of the vascular system when injected intravenously and thus, at least in part, their ability 
to be used to treat chronic circulatory disorders. 
5.2 RESULTS 
5.2.1 Development and characterization of an aloe vera based DRP 
Since high MW polysaccharides are known to be effective drag reducers [1, 6, 17] that are 
resistant to mechanical degradation [21-23], and a polysaccharide extracted from the aloe vera 
plan was found to have low systemic toxicity when injected either intraperitoneally or 
intravenously [24], it was hypothesized that AVP would be a good candidate DRP for use in the 
medical field. Previous studies have shown that AVP was an effective DRP both in vitro and in 
vivo [1, 34]. AVP, however, had not been fully characterized, and production methods were not 
reproducible. Therefore, it was important to attempt to standardize AVP extraction methods in 
order to eliminate variability between preparations, as well as to characterize this DRP. The 
results presented in Sections 5.2.2.1 to 5.2.2.5 show certain progress made toward this 
standardization and characterization of this novel DRP. Figure 5-1 shows an image of a molecule 
of AVP obtained using an atomic force microscope (AFM). 
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 Figure 5-1. AFM of aloe-derived DRP molecule (image was obtained by Brian Cusick in Dr. Tomasz 
Kowalewski’s laboratory at Carnegie Mellon University) 
 
5.2.1.1 Chemical characterization of AVP 
Identification of the chemical structure of the active drag reducing component of AVP is 
necessary before this DRP can be approved for use in the clinical setting. Using a trypsin based 
assay as well as a proteinase K based assay, the possibility that the active drag reducing 
component of aloe was a protein was ruled out. Trypsin and proteinase K are both serine 
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proteases which digest proteins by hydrolyzing peptide bonds [96, 97]. AVP maintained its drag 
reducing activity when tested in the turbulent flow system at 10 µg/ml following treatment with 
either trypsin or proteinase K. Since neither enzyme degraded the polymer, it was concluded that 
the aloe-derived DRP did not contain peptide bonds. Based on these studies and the literature 
[24, 60, 61, 63, 64, 95], it is reasonable to conclude that the drag reducing component of aloe is a 
polysaccharide residue. 
Treatment of AVP with endo-β-D-mannanse, however, did cause degradation of the 
DRP. Following treatment with endo-β-D-mannanse, the drag reducing efficiency of AVP was 
diminished. Before enzyme treatment, the AVP reduced resistance to flow by ~ 40% at a 
concentration of 10 µg/ml; after treatment, the AVP produced no drag reducing effect. Since 
endo-β-D-mannanse is known to hydrolyze mannans (galactomannans, glucomannans, and 
galactoglucomannans) containing β-1,4 linkages, it can be inferred that the drag reducing 
element of aloe likely contains a backbone comprised of β-1,4 linked mannose residues. 
5.2.1.2 GPC 
Mean weight average molecular weight of the AVP determined by GPC was 8.4 x 106 Da ± 3.0 x 
106 Da. Intrinsic viscosity was 29.3 dl/g ± 3.2 dl/g. Radius of gyration and hydrodynamic radius 
were 199 nm ± 26 nm and 153 nm ± 20 nm respectively. Polydispersity index was calculated to 
be 1.17 ± 0.17. These molecular characteristics are indicative of effective DRPs, but standard 
deviations are high. This may be due to the fact that components vary among plants depending 
on factors such as plant age [94, 95], or that slight variations may have still existed in the 
extraction procedure leading to different actual concentrations of DRP in the final preparation. 
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5.2.1.3 In vitro test of drag reducing ability 
Drag reducing ability of AVP was assessed at 10 µg/ml in turbulent flow. At a Re of 
22,000, AVP reduced resistance to flow by 31% ± 6%. Figure 5-2 shows friction factor vs. Re 
for 10 µg/ml AVP in the recirculating turbulent flow system compared to pure saline and the 
friction factor obtained using the Blasius equation (Equation 5). At a higher concentration, 100 
µg/ml, AVP was found to reduce friction by up to 50%. At a concentration of 10 µg/ml, AVP 
produced a statistically significant reduction in friction factor compared to saline (control) at all 
tested Reynolds numbers (p < 0.001) 
0.01
0.10
10000 15000 20000 25000
Reynolds Number
Fr
ic
tio
n 
Fa
ct
or
Blasius Saline 0.01 mg/ml AVP
 
Figure 5-2. Drag reducing effect of AVP 
 
As described in section 5.1.1.1, the effect of lyophilization of the drag reducing 
effectiveness of AVP was also studied. It was found that the process of lyophilization produced 
no change in the aloe polymer’s drag reducing activity. At a concentration of 10 µg/ml, the tested 
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AVP reduced resistance by 30.6% ± 2.1% prior to lyophilization compared to 29.3% ± 5.1% 
following the lyophilization process. Therefore, lyophilization could be used to provide a safe 
storage or transport method for AVP preparations.   
5.2.1.4 Viscoelasticity 
Concentrated AVP solutions demonstrated pronounced non-Newtonian behavior and high 
viscosity, which are defining characteristics of all effective DRPs. Average viscosity, elasticity, 
and relaxation time, determined at a concentration of 2.5 mg/ml in saline using the Brookfield 
cone and plate rheometer and the Vilastic 3 viscoelastometer, are shown in Figures 5-3 through 
5-6. At low concentrations AVP solutions had Newtonian flow behavior. Average asymptotic 
viscosity at a concentration of 0.1 mg/ml was found to be ~ 1.2 cP.  
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Figure 5-3. Viscosity of AVP measured in the Brookfield cone and plate rheometer at a concentration 
of 2.5 mg/ml 
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Figure 5-4. Viscosity of AVP measured in a viscoelastometer (Vilastic) at a concentration of 2.5 mg/ml 
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Figure 5-5. Elasticity of AVP measured in a viscoelastometer (Vilastic) at a concentration of 
2.5 mg/ml 
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Figure 5-6. Relaxation time of AVP measured in a viscoelastometer (Vilastic) at a concentration of 
2.5 mg/ml 
 
5.2.1.5 Mechanical degradation studies 
AVP was found to be much less susceptible to mechanical degradation than PEO in both saline 
and in the presence of RBCs. In saline, AVP retained over 50% of its original drag reducing 
efficiency after five hours of exposure to turbulent flow. The degradation rate of AVP was 
slightly faster in a 20% RBC suspension, but 40% of its original drag reduction was still 
maintained in the suspension after five hours of exposure to turbulent flow (Figure 5-7). 
Molecular characteristics of AVP, measured using GPC, did not change significantly following 
exposure. 
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Figure 5-7. The rate of degradation of AVP at 0.1mg/ml is higher in a RBC suspension than in saline, 
but AVP maintains drag reducing ability in both saline and RBC suspensions following 15 min (top) and 5 hr 
(bottom) of exposure to turbulent flow. 
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The single relaxation decay model, which was applied to PEO degradation and described 
in Section 3.1.5, model was also tried for AVP degradation, where it could be used to predict 
degradation over longer time periods than can be practically studied. However, this model did 
not fit well. Therefore, it was determined that the single relaxation decay model could not be 
used universally to predict degradation of any DRP at least in the studied recirculating flow 
system. 
5.2.2 Synthesis and characterization of poly(N-vinylformamide)  
High MW PNVF was synthesized using an inverse emulsion technique, and tested as a potential 
DRP. Since PNVF is synthesized from a non-toxic isomer of acrylamide [66, 67], and 
polyacrylamide is known to be an effective DRP, high MW PNVF was considered to have 
potential for DRP applications in vivo. 
5.2.2.1 1HNMR 
The synthesis of PNVF was confirmed by NMR, 1HNMR (D2O) δ 1.68 (br s, 2H, methylene), 
3.89 (br s, 1H, methine), and 8.0 ppm (m, 1H, formyl H). The shift at 8.0 ppm, which represents 
the formyl hydrogen, confirmed that the tested polymer was indeed PNVF and not the 
hydrolyzed form, poly(vinyl amine).  
5.2.2.2 GPC 
The synthesized PNVF had a weight average molecular weight, measured by GPC, of 4.2x106 
Da ± 1.7x105 Da with a polydispersity index of 4 prior to dialysis. Following dialysis against a 
membrane with a 1x106 Da molecular weight cutoff, the weight average molecular weight 
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increased to 4.5x106 Da ± 3.1x105 Da, and the polydispersity index was reduced to 1.4. The 
intrinsic viscosity was 4 dl/g ± 0.1 dl/g and the radius of gyration was 82 nm ± 2.4 nm. In 
comparison, PEO-4500 had a much higher intrinsic viscosity (13 dl/g) and radius of gyration 
(120 nm).   
5.2.2.3 In vitro test of drag reducing ability 
The addition of PNVF to turbulent flow produced a marked reduction in resistance to flow. 
Figure 5-8 shows the pressure vs. flow relationship for water with 0.1 mg/ml PNVF and 0.5 
mg/ml of PNVF compared to that of pure water. At a given flow rate, the PNVF solution 
required a significantly lower driving pressure than the pure water, representing the Toms effect. 
PNVF reduced resistance to turbulent flow by a maximum of 20% at a Reynolds number of 
20,000 when added into the circulating system at a concentration of 0.1 mg/ml and 32% at a 
concentration of 0.5 mg/ml. At a concentration of 0.1 mg/ml, PEO-4500 reduced drag by 36% 
while PEO-1000 and PEO-2000 reduced drag by 17% and 23% respectively. A dimensionless 
friction factor vs. Reynolds number curve for these experiments is shown in Figure 5-9. PNVF 
produced a statistically significant reduction in friction compared to saline (control) over the 
entire range of studied Reynolds numbers at both 0.1 mg/ml and 0.5 mg/ml (p < 0.001). 
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Figure 5-8. Pressure vs. flow characteristics of PNVF solutions obtained in the turbulent flow system. 
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Figure 5-9. Dimensionless friction factor vs. Reynolds number obtained for saline, PNVF (two 
concentrations) and two PEO solutions 
5.2.2.4 Viscoelasticity 
Concentrated PNVF solutions exhibited non-Newtonian behavior, a characteristic demonstrated 
by DRPs. High shear viscosity of a 5 mg/ml PNVF solution dissolved in saline was ~6 cP at a 
shear rate of 400 s-1. The viscosity vs. shear rate curves for this solution, determined using a 
viscoelastometer and a cone and plate viscometer are shown in Figure 5-10. The viscosity, 
elasticity, and relaxation time vs. shear rate curves for the PNVF, PEO-1000, and PEO-2000 
solutions dissolved in saline are shown in Figures 5-11, 5-12, and 5-13. Asymptotic viscosity of 
a 0.5 mg/ml PNVF solution was 1.3 cP and asymptotic viscosity of a 0.1 mg/ml solution was 
1.05 cP.   
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Figure 5-10. Viscosity of PNVF solution at the concentration of 5 mg/ml compared to that of two 
PEOs 
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Figure 5-11. Viscosity of PNVF solution measured in viscoelastometer at a concentration of 5 mg/ml 
compared to that of two PEOs 
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Figure 5-12. Elasticity of PNVF solution measured in viscoelastometer at a concentration of 5 mg/ml 
compared to that of two PEOs 
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Figure 5-13. Relaxation time of PNVF solution measured in viscoelastometer at a concentration of 
5mg/ml compared to that of two PEOs 
 
5.2.2.5 Mechanical degradation studies 
The PNVF initially reduced resistance to flow by 15% when added into the recirculating flow 
system at a concentration of 0.1 mg/ml and a Reynolds number of 15,000. However, the drag 
reducing efficiency of the PNVF decreased with continuing exposure to flow, vanishing within 
90 minutes of exposure. The degradation of PNVF was compared to that of PEO-1000 and PEO-
2000, which exhibited similar initial drag reducing efficiency. Figure 5-14 shows the drag 
reduction produced by these DRPs following exposure to flow induced shear stresses. PNVF 
retained over 40% of its ability to reduce resistance to flow after 30 minutes of exposure to flow 
induced shear stress and almost 25% after an hour of exposure, while the PEO-1000 lost its drag 
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reducing ability completely within 30 minutes and PEO-2000 within one hour. Average 
molecular weight of the PNVF, however, decreased only slightly over time. The change in 
molecular weight versus time of exposure to flow is shown in Figures 5-15 and 5-16. Both 
weight average (Mw) and z average (Mz) molecular weight, which represents the higher end of 
the molecular weight distribution, are shown. 
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Figure 5-14. Drag reducing ability of PNVF maintained after exposure to flow compared to that of 
several PEOs 
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Figure 5-15. Weight average molecular weight decreases slightly as the PNVF drag reducing ability 
degrades during exposure to turbulent flow 
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Figure 5-16. Z average molecular weight decreases slightly as the PNVF drag reducing ability 
degrades during exposure to turbulent flow 
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5.2.3 Characterization of high molecular weight hyaluronic acid for use as a DRP for 
potential use in vivo 
HA has long been known to have drag reducing ability [72] and currently has FDA approval for 
some biomedical applications (unrelated to its drag reducing properties) [73], making it an 
desirable candidate to be applied for enhancement of blood circulation. Therefore, several HA 
preparations, provided by Lifecore Biomedical, were characterized and evaluated for potential 
use in such applications. 
5.2.3.1 GPC 
Mw, IV, Rg, and PDI were measured for a series of HA samples. Table 5-1 shows the measured 
characteristics for each tested HA. 
 
Table 5-1. Comparison of molecular parameters of several HA samples obtained from Lifecore 
Biomedical 
Sample Mw IV Rg PDI 
  (Da) (dL/g) (nm)   
002941 1.28 x 105 4.2  26 1.5 
P9411-1 4.74 x 105 15  62 1.2 
P0207-1 1.11 x 106 20.4 80 1.9 
P9711-9 1.30 x 106 27.2 106 1.1 
 
5.2.3.2 In vitro test of drag reducing ability 
The addition of HA (with the exception of that with MW ~130 kDa) to turbulent flow produced a 
significant reduction in resistance to flow. Drag reducing effectiveness of the tested HAs 
increased with increase in concentration and with increase in Mw. Drag reduction produced by 
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the tested HA samples at various concentrations is shown in Table 5-2. The DR of the highest 
MW HA could not be tested in the flow system at 500 µg/ml since, due to its high viscosity, 
turbulent flow could not be achieved in the recirculating flow system. A dimensionless friction 
factor vs. Reynolds number curve for these experiments performed at 0.1 mg/ml is shown in 
Figure 5-17. The two HAs with MW above 106 Da produced a statistically significant reduction 
in friction compared to saline (control) over the entire range of studied Reynolds numbers (p < 
0.01), while the lower molecular weight polymers produced no significant change in friction 
factor.   
 
Table 5-2. Comparison of maximum DR produced by various HAs at several concentrations in the 
turbulent flow system. 
Sample Actual Mw Max. DR (%) Max. DR (%) Max. DR (%) Max. DR (%) 
  (Da) 10 µg/ml 100 µg/ml 250 µg/ml 500 µg/ml 
002941 1.28 x 105 0 0  0 0 
P9411-1 4.74 x 105 3 8 16 20 
P0207-1 1.11 x 106 6 17 26 37 
P9711-9 1.30 x 106 10 35 43 N/A 
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Figure 5-17. Friction factor vs. Reynolds number obtained for several HAs at 0.1 mg/ml 
5.2.3.3 Viscoelasticity 
Concentrated HA solutions with MW ~ 500 kDa and above exhibited non-Newtonian behavior, a 
well-known property of DRPs. The viscosity vs. shear rate curves for these solutions at a 
concentration of 2.5 mg/ml, determined using a cone and plate viscometer, are shown in Figure 
5-18. Due to the very high solution viscosity of HA with MW of 1100 kDa and 1300 kDa, it was 
not possible to obtain viscosity at higher shear rates. The viscosity, elasticity, and relaxation time 
vs. shear rate curves for the 2.5 mg/ml HA solutions, measured using the Vilastic 3 
viscoelastometer, are shown in Figures 5-19, 5-20, and 5-21. Elasticity and relaxation time are 
negligible for the lower MW polymers and are therefore shown only for the two highest MW 
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HAs. Viscosities at a concentration of 0.1 mg/ml were measured using capillary viscometers and 
are shown in Table 5-3. 
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Figure 5-18. Viscosity of HA solutions at a concentration of 2.5 mg/ml  
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Figure 5-19. Viscosity of HA solutions measured in viscoelastometer at a concentration of 2.5 mg/ml 
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 Figure 5-20. Elasticity of HA solutions measured in viscoelastometer at a concentration of 2.5 mg/ml 
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Figure 5-21. Relaxation time of HA solutions measured in viscoelastometer at a concentration of 2.5 
mg/ml 
 
Table 5-3. Viscosities of HAs measured using a capillary viscometer at a concentration of 0.1 mg/ml 
at 22 °C ± 1°C. 
Sample Actual Mw Capillary viscosity 
  (Da) at 0.1 mg/ml (cP) 
002941 1.28 x 105 1.09 
P9411-1 4.74 x 105 1.17 
P0207-1 1.11 x 106 1.27 
P9711-9 1.30 x 106 1.33 
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5.2.3.4 Mechanical degradation studies of HA 
The HA with MW ~ 1300 kDa initially reduced resistance to flow by 20% when added into the 
flow system at a concentration of 0.1 mg/ml and a Reynolds number of 15,000. The HA 
maintained its drag reducing efficiency well with continuing exposure to flow. The degradation 
of HA was compared to that of PEO-1000 and PEO-2000. Figure 5-22 shows the drag reducing 
ability of these DRPs following exposure to flow induced shear stresses. HA maintained over 
90% of its original drag reducing ability throughout the entire five hours of exposure to turbulent 
flow. The PEO-1000 lost its drag reducing ability completely within 30 minutes and PEO-2000 
within one hour. 
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Figure 5-22. Percentage of original drag reducing ability maintained after exposure to flow 
 123 
5.2.4 Comparison and correlation the DRP physicochemical and rheological properties 
with their drag reducing activity 
In order to help identify the best candidates for a DRP to be used for biomedical applications, as 
well as the properties which would best define drag reducing effectiveness, the molecular and 
rheological properties, drag reducing ability, and mechanical degradation of several DRPs, 
including well-known DRPs such as PAM and PEO as well as novel DRPs such as AVP, HA, 
and PNVF, were compared. 
5.2.4.1 Correlations between DRP physicochemical and rheological properties and their 
drag reducing effectiveness 
Correlations were investigated between drag reducing efficiency and polymer properties 
including MW, Rg, IV, concentrated solution viscosity, elasticity, and relaxation time for PEO-
4500, PAM (Praestol 2510, Stockhausen, Inc.), AVP, PNVF, HA (P9711-9, Mw ~ 1300 kDa), 
and dextran. Drag reducing ability was found to best correlate with relaxation time measured in 
concentrated solutions (r2 = 0.85 at a shear rate of 50 s-1 and r2 = 0.82 at 500 s-1) and radius of 
gyration (r2 = 0.85).  Elasticity in concentrated solutions (r2 = 0.64 at a shear rate of 50 s-1 and r2 
= 0.60 at 500 s-1) and IV (r2 = 0.63) also correlated fairly well with drag reducing effectiveness. 
Solution viscosity did not correlate with drag reducing ability as well as the other tested 
parameters did (r2 = 0.50 at a shear rate of 50 s-1 and r2 = 0.34 at 500 s-1). Molecular weight was 
found to be a good predictor of polymer drag reducing ability within the class of DRPs (r2 = 
0.90). However, no correlation was found between drag reducing ability and Mw for polymers in 
general. For example, the tested dextran had the highest Mw of all the tested polymers, but it had 
no drag reducing ability. 
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5.2.4.2 Correlations between DRP physicochemical and rheological properties and their 
effects in microflow of RBCs 
Correlations were determined between the effects of DRPs on flow of RBCs in microchannels 
and their physical properties including MW, Rg, IV, concentrated solution viscosity, elasticity, 
and relaxation time for PEO-4500, PAM (Praestol 2510), AVP, and HA (Hyvisc, Boehringer 
Ingelheim Vetmedica).  
Observed near wall plasma layer size was determined to best correlate with relaxation 
time measured at high shear rate in solutions with a concentration of 2.5 mg/ml (r2 = 0.92 at a 
shear rate of 500 s-1) and with radius of gyration (r2 = 0.98). Since polymers with larger gyration 
radii and relaxation times led to lower reduction in near wall plasma layers, it can be concluded 
that DRPs which have lower Rg and relaxation time were more effective in altering flow of 
RBCs in microchannels. It should be noted that this is true only within the class of DRPs. 
Polymers such as PEO-200 and high molecular weight dextran, which had no drag reducing 
properties, had no effect on flow of RBC suspension in microchannels even though their Rg and 
relaxation time were the lowest of the studied polymers. Intrinsic viscosity (r2 = 0.64) and 
elasticity measured at high shear rate in concentrated solutions (r2 = 0.64 at a shear rate of 500 s-
1) also predicted the effect of DRPs on plasma layer size fairly well. 
5.2.4.3 Comparison of mechanical degradation behavior among the class of DRPs 
Comparison of the mechanical degradation rates of different DRPs was important since it is 
necessary for the DRPs to be able to withstand shear forces in the body for some length of time, 
especially for use in treating chronic circulatory disorders. AVP was found to be the most 
effective drag reducer of the tested polymers at the starting point of the hydrodynamic tests, 
reducing resistance to flow by 50% at 0.1 mg/ml and a Reynolds number of ~ 20,000. PAM 
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(Praestol 2510) was also very effective, reducing resistance by 45% under the same conditions, 
followed by PEO-4500 (40%), HA (P9711-9, Mw ~ 1500 kDa) (22%), and PNVF (13%) tested at 
the same concentration. Following 15 minutes of exposure to stresses in the turbulent flow 
recirculating system, AVP was still the most effective DRP (50 % DR or 100% of its original 
DR) followed by PAM (30% or 67% of its original DR), HA (20% or 91% of its original DR 
PEO (8% or 20% of its original DR), and PNVF (7% or 54% of its original DR). AVP remained 
the most effective DRP after one hour (40% or 80% of its original DR) followed by HA (20% or 
91% of its original DR), PAM (15% or 33% of its original DR), PNVF (3% or 23% of its 
original DR), and PEO (2% or 5% of its original DR). After five hours of exposure to flow, AVP 
continued to be the most effective DRP (30% DR, 60% of original DR) followed by HA (20%, 
91% of the original DR), and PAM (5% or 11% of original DR). Both PEO and PNVF 
completely degraded within five hours of exposure. Figure 5-23 shows the percentage of original 
drag reducing effectiveness maintained after one hour of exposure to flow. The polysaccharides, 
HA and AVP, were found to be the most resistant to mechanical degradation of the tested 
polymers. 
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Figure 5-23. Percentage of original drag reducing effectiveness maintained after one hour of 
exposure to flow 
5.3 DISCUSSION 
DRPs have been shown to improve impaired blood circulation caused by numerous pathologies 
in animal models [1-4, 6, 9, 12, 16]. Although commonly used DRPs such as PEOs, PAMs, and 
plant derived polysaccharides are very effective in these models, they are not optimal for 
potential clinical applications. PEO is degraded quickly by high stresses [45], PAM presents 
toxicity issues [9, 12, 93], and natural polymers are often difficult to manufacture consistently in 
the necessary quantities. Therefore, the search continues for better synthetic or easily produced 
natural DRPs, which are resistant to mechanical degradation, biocompatible, well reproducible, 
 127 
and easy to manufacture, for potential clinical use. The three polymers discussed in this section, 
an aloe derived polysaccharide, poly(N-vinylformamide), and hyaluronic acid, all proved to be 
effective DRPs, and have physicochemical characteristics attractive for use in clinical 
applications. 
AVP was found to be the most effective drag reducer of the tested polymers, reducing 
resistance to turbulent pipe flow by up to 50% at the accessible range of Reynolds numbers in 
the turbulent flow system used for these studies. The active drag reducing component was 
determined to be a polysaccharide consisting of β-1,4 linked mannose residues, but additional 
studies are needed to elucidate the exact chemical structure of this polymer. Molecular and 
rheological properties of AVP are typical for an effective drag reducer. High standard deviations 
in molecular and rheological properties are likely the result of variations between aloe 
preparations caused by variations between plants, or slight variance in the extraction procedure. 
The fact that standard deviations in viscoelastic parameters are highest at low shear rates may 
also indicate the presence of some molecular aggregation which varied between samples. This 
aggregation was also likely to be responsible for the higher viscosities measured using the cone 
and plate rheometer compared to those measured using the Vilastic viscoelastometer. The 
oscillatory flow in the viscoelastometer could break up these aggregates significantly reducing 
the observed viscosity, especially at low shear rates.    
AVP was much more resistant to mechanical degradation than PEO in both saline and in 
the presence of RBCs making it a promising candidate for potential use in treatment of chronic 
circulatory disorders. It has been previously hypothesized that certain polysaccharides may have 
increased resistance to degradation due to their strong bonds between monomer units as well as 
intra- and intermolecular interactions lessening the stresses on those bonds [22]. It has also been 
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suggested that branches on a polymer molecule increase its mechanical stability [23]. Although 
the exact structure of the DRP component of aloe is not yet known, a structure proposed for the 
main component of the aloe polysaccharide may contain some branches [60] while PEO does 
not. Finally, since polysaccharides, such as the aloe-based polysaccharide, are comprised of 
numerous six-carbon rings linked together, the molecules are more rigid, and therefore 
degradation is not entropically favored [21]. The presence of rings could also allow for some 
bonds to be broken without breaking up the polymer backbone. Therefore, unlike PEO, the aloe 
polymer could likely withstand some bond breakage without compromising its drag reducing 
activity. The degradation of AVP caused by biologic mechanisms in vivo, however, has not been 
studied, but must be evaluated before AVP could be used clinically. 
 Unlike the natural AVP, the synthetic nature of PNVF makes production in large 
quantities and consistent batches more feasible. Therefore, high molecular weight PNVF 
(4.5x106 Da) was synthesized and tested as a DRP for possible biomedical applications. The 
synthesized PNVF had molecular properties characteristic of DRPs, including high molecular 
weight and relatively large intrinsic viscosity and radius of gyration, and was effective in 
reducing resistance to turbulent flow. While the PNVF was shown to be an effective drag-
reducer, reducing resistance to turbulent flow by over 30% at a concentration of 0.5 mg/ml at 
turbulent flow conditions produced in the recirculating system, it was not as effective as PEO of 
the same molecular weight (4.5x106 Da). One possible explanation for this is that, since NVF 
polymerization is known to exhibit some chain transfer [66], the PNVF is likely not entirely 
linear. This hypothesis is supported by the fact that its intrinsic viscosity (4 dl/g) is significantly 
lower than the 13 dl/g intrinsic viscosity of PEO-4500. Another factor that may contribute to this 
difference in drag reducing efficiency is that the molecular weight of the NVF monomer is much 
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higher that the molecular weight of the ethylene oxide monomer. It is well known that, at the 
same polymer molecular weight, the polymer with the lower monomer molecular weight and 
therefore a higher degree of polymerization is a better drag-reducer [26]. The drag reducing 
ability of the PNVF is close to that of PEO-1000 and PEO-2000 (at least in the applied range of 
Reynolds numbers). In addition, viscoelastic properties of the PNVF correspond well to these 
two PEOs, indicating that the viscosity, elasticity, and relaxation time are important parameters 
in determining a polymer’s drag reducing activity.   
 Although PNVF was susceptible to mechanical degradation, losing all of its drag 
reducing ability after 90 minutes of circulation in the turbulent flow system, its degradation rate 
was significantly lower than that of PEO-1000 and PEO-2000, which lost their drag reducing 
ability after circulation for 20 and 45 minutes respectively at the same concentration and 
identical flow conditions. While there was a significant loss of drag reducing ability over time 
for both PNVF and PEO, the molecular weight of PNVF decreased only slightly. These results 
are consistent with previously published studies of mechanical degradation of drag reducing 
polymers [49, 51]. Two theories have been proposed to explain this phenomenon, which is also 
seen in polyacrylamide degradation. The first of these theories is the molecules at the high end of 
the molecular weight distribution are most influential in a determining a DRP’s efficiency [98] 
and scission of those molecules would account for loss in drag reducing ability. This is supported 
by the decrease in Mz, which defines the high end of the molecular weight distribution. The 
second hypothesis proposes that shear induced structure formation and molecular aggregation are 
partially responsible for the DRP effects, and therefore, the irreversible breakup of these 
structures is responsible for the declining drag reducing effect produced by polymers [49, 51]. 
The drag reducing ability of the PNVF was not restored after stopping the flow for one hour. 
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This is consistent with the experiments of Liberatore et al, suggesting that that polymer 
aggregates contribute to the drag reducing ability and irreversibly break up as the solution 
degrades [49]. The loss of the high molecular weight fraction of the PNVF during exposure to 
high mechanical stresses might also be responsible for the loss of the polymer’s ability to form 
molecular aggregates since flow-induced structure formation is highly dependent on molecular 
weight [49, 99]. Sellin et al. suggested a similar theory for PEO degradation, proposing that both 
chain scission and disentangling of molecular agglomerates could contribute to DRP degradation 
[52]. Although there is evidence that either of these theories or a combination of them could 
explain the loss of drag reducing ability, the mechanisms behind the degradation of DRPs and 
the drag reducing phenomenon itself are still not completely understood, and therefore, it is 
likely that a combination of these theories and other factors may contribute to the degradation of 
PNVF. Due to its higher stability against mechanical stress than PEO, PNVF might be a more 
favorable polymer for chronic medical uses.     
 In vitro and in vivo studies showed that the PNVF seemed to be biocompatible with blood 
[39]. Preliminary in vivo studies showed that PNVF was efficient in reducing vascular resistance 
without producing adverse effects, at least in acute experiments [39]. However, further in vivo 
studies are necessary to prove beneficial effects of PNVF on normal and especially on 
pathological blood circulation. Nevertheless, due to its obvious drag reducing effectiveness at 
both in vitro and in vivo flow conditions, relatively slow mechanical degradation, and its very 
low toxicity, PNVF can be considered as a DRP for potential biomedical applications. 
HA, at MW above 106 Da, possessed molecular and rheological characteristics indicative 
of DRPs. This natural polymer is available commercially and has been used in some medical 
applications [70, 71, 100], making it more attractive for the potential translation to clinical use as 
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DRP than AVP. In this study, HA was proven to be an effective drag reducer which was more 
resistant to mechanical degradation than any of the tested polymers. As with AVP, this increased 
resistance to mechanical degradation is likely due to the strong bonds between monomer units, 
characteristic of polysaccharides, and intra- and intermolecular interactions reducing stresses on 
those bonds [22] as well as the ring-like structure of the monomer units providing stability. A 
concern with HA, however, is degradation caused by biological mechanisms in vivo. HA was 
found to degrade quickly in the blood stream, and the main method of HA removal from the 
blood is by endothelial cells of liver sinusoids [100]. This is an issue that would need to be 
addressed before HA can be used clinically for treating circulatory diseases as a DRP. 
Various water-soluble DRPs have been shown to enhance blood flow in animal models of 
several pathologies including diabetes hemorrhagic shock and myocardial ischemia [1-4, 6, 8-10, 
12, 14, 16, 17, 53]. It was shown that the effective biological half life of one DRP, PAM 
(Separan AP-30), was about 35 hours in rats [53]. Mechanical degradation could be at least 
partially responsible for this observed loss of effectiveness. PEO was shown to be one of the 
most effective drag reducers among well known DRPs and was used in many in vitro and in vivo 
studies. Mechanical degradation, however, is a serious concern when considering using DRPs for 
potential chronic treatment of patients. The stresses produced by cell motion in blood flow, as 
evidenced in the current studies, cause even more rapid degradation of PEO. AVP, PNVF, and 
HA, as well as PAM, were shown to degrade more slowly than PEO when exposed to 
mechanical stresses.  
The possibility that the decreased drag reducing ability may be a result of the polymer 
adhering to the tube and pump walls and, thus, reduction of its concentration in the flowing 
solution was considered in this study. The concentration of polymer in solution during five hours 
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of turbulent flow, determined using a refractive index detector, remained constant throughout the 
experiment, and therefore the loss in drag reducing activity was not caused by polymer 
adherence to the wall. More studies need to be done to further understand the DRP degradation 
mechanisms. For potential biomedical use, it would be beneficial to have a DRP that degrades 
relatively slowly since it can last for a significant amount of time after intravascular injection. 
Considering that the blood flow in the cardiovascular system is not turbulent and that the shear 
stresses in the in vitro turbulent flow systems are significantly higher than physiological shear 
stresses, one can expect much a longer time of DRP circulation in vivo without degradation than 
that in the in vitro turbulent flow system used in these studies. 
A surprising result found in these studies was that, within the class of DRPs, polymers 
which have lower Rg and IV and exhibit shorter relaxation times and lower elasticity in 
concentrated solutions are more effective in redistributing RBCs in microchannels. The 
mechanism by which the DRPs alter RBC distribution in microchannels remains unknown, and, 
therefore, the properties necessary for this phenomenon have yet to be identified. One possible 
explanation is that the effectiveness of DRPs on microflow is based on flexibility of the polymer 
molecules. It was shown that, of the tested DRPs, those which have the lower monomer weight, 
and are thus more flexible, are more effective in altering microchannel blood flow. This is 
supported by the fact that DRPs which have lower elasticity, gyration radii, and intrinsic 
viscosities, and therefore higher flexibility, performed best in RBC microflow experiments.    
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6.0  SUMMARY 
6.1 CONCLUSIONS 
A series of tests was developed to effectively evaluate and characterize water soluble DRPs for 
possible clinical use in treating circulatory disorders and to further elucidate mechanisms of their 
beneficial effects on blood circulation in vivo.  
The mechanism responsible for the DRP beneficial effects in the microcirculation was 
explained, at least in part, by the redistribution of RBCs flowing in the microcirculation, leading 
to a reduction of near wall plasma layer size and thus attenuation of plasma skimming at 
microvessel bifurcations. This, in turn, can improve gas transport between RBCs and the tissue 
by significantly reducing the diffusion distance of gas molecules, as well as increase shear stress 
on microvessel walls which would promote the release of shear stress dependent vasodilators, 
leading to local vasodilation and a decrease in overall vascular resistance.  
Additionally, this study provided a better understanding of mechanical degradation 
behavior of DRPs exposed to flow induced shear stresses, especially in the presence of particles 
such as RBCs in a flowing solution. It was found that an increase in particle concentration led to 
an increase in degradation rate, and that presence of rigid particles led to an even larger 
degradation rate increase than deformable RBCs. 
 134 
Finally, three blood soluble DRPs with great potential for clinical use were characterized 
and evaluated. These DRPs offer advantages of biocompatibility and resistance to stress induced 
degradation over several of the commonly used DRPs. An aloe derived polysaccharide was 
found to produce the largest drag reducing effect of any of the tested polymers. It proved to be 
relatively resistant to mechanical degradation, and is likely non-toxic since some studies have 
shown that the injection of aloe inner gel derived products produced little systemic toxicity [24]. 
Poly(N-vinyl formamide) was synthesized from a non-toxic isomer of acrylamide and found to 
be an effective drag reducer which, given its synthetic nature, could be easily manufactured. 
Finally, high molecular weight hyaluronic acid, a natural DRP which is currently used in certain 
medical applications, was found to be a good drag reducer and was most mechanically stable of 
any of the tested DRPs.  
This study also lead to a better understanding of the characteristics that best predict a 
DRP’s effectiveness, both in turbulent pipe flow and on blood flow in microchannels. Two 
parameters, relaxation time in relatively concentrated solution (2.5 mg/ml) and gyration radius of 
the polymer molecules, were found to be the physicochemical properties which are most 
indicative of a polymer’s effectiveness in both cases. However, while larger radius of gyration 
and intrinsic viscosity, longer relaxation time, and higher elasticity are characteristic of better 
turbulent flow drag reducers, polymers within the class of DRPs which exhibit smaller gyration 
radii, lower solution relaxation times and elasticity, and lower intrinsic viscosities, were actually 
more effective in altering the microflow of blood, and would therefore be most likely to have the 
largest effect in microcirculation in vivo.  
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The combination of these studies provided a significant step in the development of this 
novel therapy, aimed at treating impaired circulation caused by a number of pathologies, toward 
clinical use.   
6.2 STUDY LIMITATIONS 
While the performed DRP degradation study provided an effective, comparative assessment of 
the relative ability of polymers to resist stress induced degradation, there were several limitations 
in this study. The flow conditions necessary to quantify mechanical degradation using turbulent 
flow drag reduction, as well as to compare degradation over relatively short exposure times, 
produced shear stresses significantly higher than those found in the normal vascular system. 
Therefore, only relative resistance to degradation, and not actual lifetime of DRPs in circulation, 
could be determined from this study. Another limitation is that this study quantifies only 
mechanical degradation and not degradation that would be produced by biological mechanisms 
such as enzymatic degradation. It would be advantageous to investigate biological degradation in 
the future since the polymers will be exposed to various enzymes in the vascular system. Finally, 
the shear stresses encountered inside the pump head were not considered in this study. Since all 
polymers were exposed to similar flow conditions in the pump, the comparative study is valid. 
However, the magnitude of this stress and exposure time must be determined in order to 
accurately quantify the magnitude of shear stress which caused the observed degradation. 
Another major limitation of this study is that, although the work represents significant 
progress toward the elucidation of the mechanisms of the intravascular DRP phenomenon, the 
exact mechanism remains unknown. One of the potential mechanisms of the intravascular DRP 
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effect was found to involve redistribution of RBCs across vessels in the microcirculation, 
reducing the size of the near wall plasma layer and delivering more RBCs to the smaller vessels 
and thus capillaries. In vivo, this would likely lead to improved oxygen transport as well as local 
vasodilatation which could account for the decrease in vascular resistance observed in animal 
models. Although the current work has provided a much better understanding of the action of the 
DRPs in the vascular system, the exact mechanisms of the intravascular DRP effect, including 
the mechanism by which DRPs are preventing relocation of RBCs toward the center of the 
microtube/microvessel, still remain unknown. One hypothesis for the DRP effect on distribution 
of RBCs is that the polymers align along the flow paths and diminish RBC rotation, which is 
important factor in the development of a near-wall plasma layer in microvessels [1]. 
Additionally, the increase in blood viscoelasticity caused by DRPs may strengthen non-
Newtonian patterns of the axial velocity profile, blunting the velocity profile and shifting mean 
RBC velocity closer to that of the blood [1]. Examination of these hypotheses would help to 
further elucidate mechanism by which DRPs act in vivo.  
 There were several other limitations in the in vitro microflow studies that should 
be addressed in order to further understand the actions of DRPs in blood flow. One such 
limitation was that the in vitro experiments to determine the effects of DRPs on blood flow in 
microchannels were performed in steady flow in rigid tubes, while, in vivo, blood flow is 
pulsatile and vessels are distensible. Steady flow was applied in these studies in order to allow 
for quantification and simpler modeling, as well as due to the known fact that the pulsatility is 
diminished in the microcirculation [59, 86]. However, physiological blood flow, even on the 
microcirculatory level, does exhibit some pulsatility. It was discovered that the Fåhraeus effect 
also occurred in pulsatile blood flow [101]. Therefore, studies of the DRP effects on pulsatile 
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blood flow in microchannels would help to determine whether DRPs had the same effect on 
reduction of near wall plasma layer in unsteady flow as in steady flow. Additionally, although 
blood vessels in vivo are distensible, the microflow studies in this project were performed in 
tubes with rigid walls. This allowed for the quantification of DRP effects on wall shear stresses 
via measurements of pressure gradients across a microchannel. If an increase in pressure gradient 
was seen with the addition of DRP to blood, it could be assumed that in an in vivo situation this 
would cause vasodilation. A study of DRP effects on blood flowing in distensible vessels would 
provide further understanding of the effects of DRPs on the microcirculation.  
Finally, some limitations are presented in the imaging and image analysis methods. It was 
difficult to obtain images with no flow due to RBC sedimentation as well as due to the fact that 
even with the pump stopped some residual flow still existed, and delay of imaging would change 
the near wall RBC concentration due to their sedimentation. Therefore, due to this slow flow, 
some slight RBC elongation was observed in some images taken when the pump was stopped. 
Additionally, in order to quantify the plasma layer size, the near wall area which did not contain 
cells had to be selected manually. Therefore, this determination of the exact edge of the cell free 
layer is a possible source of error in measurement of plasma layer size. 
In general, the limitations of the study relate to the fact that the experiments were 
performed in vitro, and that the real vascular system is much more complex than the models that 
were developed and applied in this work. Biological factors as well as the complex environments 
that the polymers would encounter vivo have not yet been sufficiently addressed. While 
additional in vitro experiments could help to provide more insight on the polymers action in the 
vascular system, ultimately, the complete behavior of DRPs in the vascular system will be able 
to be determined only through in vivo studies. 
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6.3 FUTURE STUDIES 
The mechanism of the intravascular DRP effect was found to involve redistribution of 
RBCs across vessels in the microcirculation, reducing the near wall cell-free plasma layer size 
and leading to improved oxygen transport and, potentially, local vasodilatation. Although the 
current work has provided a much better understanding of the action of the DRPs in the vascular 
system, an important future study would involve elucidation of the mechanism by which DRPs 
are causing relocation of RBCs. It was hypothesized that alignment and stretch of the polymers 
along flow paths may diminish RBC rotation, which is an important factor in the formation of a 
near-wall plasma layer in microvessels [1]. However, this hypothesis has not been confirmed 
experimentally yet. An increase in blood viscoelasticity caused by DRPs may also strengthen 
non-Newtonian patterns of the axial velocity profile, blunting the velocity profile and shifting 
mean RBC velocity closer to the mean velocity of blood [1]. Evaluation of these hypotheses 
would lead to a better understanding of the mechanism by which DRPs facilitate blood flow in 
vivo. 
While the DRPs developed and characterized for biomedical applications show promise, 
much more work is still needed before these polymers can be used clinically. The candidate 
polymers were all shown to be effective drag reducers that are at least somewhat resistant to 
mechanical degradation. In the case of AVP [1] and PNVF [39], preliminary in vitro and in vivo 
studies have shown biocompatibility and efficacy. However, in order for these polymers to be 
used clinically, additional animal studies, including a formal toxicity investigation, must be 
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completed. Biological degradation must be considered along with mechanical degradation in 
order to determine the length of time that DRPs, in particular the polysaccharides (AVP and HA) 
will be effective in improving blood flow in the body. In the case of AVP, additional work to 
standardize the extraction process and further characterization of the DRP composition are also 
needed before clinical use can be considered. These additional studies would continue the 
progress of this novel therapy for impaired microcirculation toward clinical use.  
 Finally, while this project provided a comparative study of DRP mechanical degradation 
which could be used to determine which polymers were most mechanically stable, shear stresses 
inside the pump incorporated in the turbulent flow system need to be determined in order to 
quantify their effects on DRP degradation. Using computational fluid dynamics to evaluate 
stresses experienced in the pump would allow for a better understanding of the mechanical 
degradation of DRPs which could ultimately be used to predict degradation caused by shear 
stress experienced in vivo. Investigation of the degradation of DRPs at different concentrations 
would also be a useful study in evaluating the mechanical stability of DRPs. 
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APPENDIX A 
PROPAGATION OF ERROR 
Propagation of error is based on Equation 22 [102, 103]. 
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where λ is a computed quantity calculated from α, β, and γ, which are measured or previously 
calculated quantities with known uncertainty, σ. The differentials in Equation 22 represent the 
change in λ with change in any of the measured or previously calculated quantities.   
In the case of addition, given by Equation 23 
γβαλ ++=           (23) 
the differentials in Equation 22 are determined to be  
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Substitution of Equation 24 into Equation 22 gives the following equation for propagation of 
error in the case of addition. 
2222
γβαλ σσσσ ++=          (25) 
In the case of multiplication, 
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αβγλ =  ,          (26) 
the differentials in Equation 22 are evaluated as follows. 
 βγα
λ =
d
d           (27) 
αγβ
λ =
d
d           (28) 
αβγ
λ =
d
d           (29) 
Substituting Equations 27, 28, and 29 into Equation 22, the following Equation for propagation 
of error in the case of multiplication can be derived. 
( ) ( ) ( ) 22222 γβαλ σαβσαγσβγσ ++=        (30) 
Equation 30 can be simplified by dividing through by 
2222 γβαλ =           (31) 
to give 
2222 %%%% γβαλ σσσσ ++=         (32) 
where %σi is defined as 
%100*%
i
i
i
σσ =          (33) 
In the case of multiplication of the quantities raised to some power, 
cba γβαγ =           (34) 
the differentials in Equation 22 can be evaluated as follows. 
cbaa
d
d γβαα
λ 1−=          (35) 
cabb
d
d γαββ
λ 1−=          (36) 
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abcc
d
d αβγγ
λ 1−=          (37) 
Substituting Equations 35, 36, and 37 into Equation 22, the following equation for propagation 
of error can be derived. 
( ) ( ) ( ) 2212212212 γβαλ σαβγσγαβσγβασ abccabcba cba −−− ++=    (38) 
The expression can be simplified by dividing through by Equation 39 to obtain Equation 
40. 
cba 2222 γβαλ =          (39) 
2222222 %%%% γβαλ σσσσ cba ++=        (40) 
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APPENDIX B 
FRICTION FACTOR ERROR ANALYSIS 
Friction factor can be calculated using Equation 4. 
2
25
8 Ql
Pd
⋅⋅⋅
⋅⋅= ρ
πλ          (4)          
Since λ is calculated through multiplication of variables raised to some exponent, percent error 
can be calculated using Equation 40.  
2222222 %%%% γβαλ σσσσ cba ++=         (40) 
For a given flow system, the quantity ρ
π
⋅⋅
⋅
l
d
8
25
 is a constant based on geometry and fluid 
properties. Therefore, the percent error for friction factor can be calculated by 
2222 %)2(%% QP σσσ λ −+=  
For the turbulent flow system, the flow probe accuracy is ± 2% [104]. Pressure transducer 
accuracy is ± 0.25% [105]. Therefore,  4% for the turbulent flow studies. =2% λσ
Equation 40 can also be used to determine error for the friction factor in laminar flow 
studies. Flow rate accuracy for the syringe pump (σQ) is ± 0.35% [106], and pressure transducer 
accuracy (σP) is ± 0.25% [105]. Therefore σλ is calculated to be 0.74%. 
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